{
  "company": "Guardant Health",
  "ticker": "GH",
  "period": {
    "from": "2026-03-03",
    "to": "2026-04-02",
    "days": 30
  },
  "sentiment_breakdown": {
    "positive": 71,
    "negative": 84,
    "neutral": 67
  },
  "synthesis": {
    "executive_summary": "**Executive Summary: Guardant Health (GH) Sentiment Analysis**\n\nSentiment analysis for Guardant Health (GH) from March 3 to April 2, 2026, indicates a slightly negative overall sentiment across 222 monitored items. The breakdown shows 84 negative mentions (38%), 71 positive (32%), and 67 neutral (30%). The primary positive driver was the recognition of Guardant Health's oncology innovation, specifically its Shield multi-cancer detection test. Conversely, negative sentiment was largely influenced by broader oncology research challenges and calls for increased funding in cancer research, rather than direct negative news about Guardant Health's operations or products.\n\nThe most significant positive event was Guardant Health receiving the Oncology Product Innovation of the Year award at the Healthcare Asia Medtech Awards 2026 for its Shield multi-cancer detection test. This accolade followed the test's recent launch in Hong Kong, Singapore, and the Philippines, supported by a partnership with Manulife. On the negative side, notable items included a scientific publication detailing resistance to ERα antagonists in breast cancer treatment and advocacy efforts urging Congress to fund new colorectal cancer research. While these reflect general challenges in oncology, they contribute to the overall cautious sentiment surrounding the sector.",
    "key_findings": [
      "✓ Show HN: Open Source 'Conductor + Ghostty'",
      "✓ Guardant Health gets oncology innovation accolade at Healthcare Asia Medtech Awards 2026",
      "✓ Holding it all together: Family caregivers’ support needs after very early supported discharge post stroke",
      "✗ Loss of luminal lineage drives resistance to next-generation ERα antagonists in pretreated ER(+) HER2(-) locally-advanced or metastatic breast cancer.",
      "✗ Police Gun Down Suspected Armed Robber on Atebubu–Ejura Highway",
      "✗ Colorectal Cancer Advocates Urge Congress to Fund New Research"
    ],
    "overall_sentiment": "mixed"
  },
  "top_positive": [
    {
      "title": "Show HN: Open Source 'Conductor + Ghostty'",
      "date": "2026-03-27",
      "source": "news",
      "score": 0.883
    },
    {
      "title": "Guardant Health gets oncology innovation accolade at Healthcare Asia Medtech Awards 2026",
      "date": "2026-04-01",
      "source": "alpha_vantage",
      "score": 0.881
    },
    {
      "title": "Holding it all together: Family caregivers’ support needs after very early supported discharge post stroke",
      "date": "2026-03-26",
      "source": "news",
      "score": 0.88
    },
    {
      "title": "Heath Goldfields Has Brought Renewed Hope To Prestea-Bogoso -Group",
      "date": "2026-03-31",
      "source": "news",
      "score": 0.844
    },
    {
      "title": "Determination of factors that allow cryogenic nanoscopy with high power illumination without devitrification",
      "date": "2026-03-31",
      "source": "news",
      "score": 0.832
    },
    {
      "title": "Donors cheer up SHS Arts students for decorating Asokwa Interchange",
      "date": "2026-03-30",
      "source": "news",
      "score": 0.827
    },
    {
      "title": "Guardant Health wins at Healthcare Asia Medtech Awards 2026",
      "date": "2026-03-27",
      "source": "alpha_vantage",
      "score": 0.772
    },
    {
      "title": "wizardenv added to PyPI",
      "date": "2026-03-30",
      "source": "news",
      "score": 0.758
    },
    {
      "title": "Fashion Designer remanded over alleged possession, use of counterfeit money",
      "date": "2026-03-27",
      "source": "news",
      "score": 0.758
    },
    {
      "title": "Mikael Barbero: Don't become the next Trivy: how to make your releases, tags, and automation resistant to compromise",
      "date": "2026-03-26",
      "source": "news",
      "score": 0.751
    }
  ],
  "top_negative": [
    {
      "title": "Loss of luminal lineage drives resistance to next-generation ERα antagonists in pretreated ER(+) HER2(-) locally-advanced or metastatic breast cancer.",
      "date": "2026 Apr 1",
      "source": "pubmed",
      "score": -1.0
    },
    {
      "title": "Police Gun Down Suspected Armed Robber on Atebubu–Ejura Highway",
      "date": "2026-03-30",
      "source": "news",
      "score": -0.95
    },
    {
      "title": "Colorectal Cancer Advocates Urge Congress to Fund New Research",
      "date": "2026-03-27",
      "source": "news",
      "score": -0.945
    },
    {
      "title": "Nsein chief gives Lower Axim counter three-month ultimatum to vacate his land",
      "date": "2026-04-01",
      "source": "news",
      "score": -0.905
    },
    {
      "title": "Businessman Jailed 24 Months for GH¢180,000 Visa Fraud",
      "date": "2026-03-27",
      "source": "news",
      "score": -0.9
    },
    {
      "title": "Two Jailed for Stealing Motorbike Worth GH¢10,500",
      "date": "2026-03-27",
      "source": "news",
      "score": -0.883
    },
    {
      "title": "Biobanking of gynecologic cancer biospecimens: Development, quality control, and translational applications",
      "date": "2026-03-31",
      "source": "news",
      "score": -0.869
    },
    {
      "title": "Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial",
      "date": "2026-03-27",
      "source": "news",
      "score": -0.869
    },
    {
      "title": "Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaboration.",
      "date": "2026 Mar 2",
      "source": "pubmed",
      "score": -0.869
    },
    {
      "title": "Comparison of first-line cetuximab and panitumumab plus doublet chemotherapies for left-sided colorectal cancer: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum.",
      "date": "2026 Mar 4",
      "source": "pubmed",
      "score": -0.869
    }
  ],
  "raw_data": {
    "total_items": 222,
    "items": [
      {
        "source": "alpha_vantage",
        "title": "Director at Guardant Health (GH) acquires 155 shares via RSUs",
        "url": "https://www.stocktitan.net/sec-filings/GH/form-4-guardant-health-inc-insider-trading-activity-0a86624789a6.html",
        "date": "2026-04-01",
        "summary": "Guardant Health director Steve E. Krognes acquired 155 shares of Common Stock by exercising Restricted Stock Units. This transaction on March 31, 2026, was a routine equity-compensation event at an exercise price of $0.00 per share. Following this, Krognes' direct holdings in Common Stock increased to 19,208 shares, and he retains 463 Restricted Stock Units.",
        "sentiment_score": 0.048732,
        "sentiment_label": "Neutral",
        "relevance_score": 0.322266,
        "sentiment": {
          "label": "positive",
          "score": 0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Guardant Health gets oncology innovation accolade at Healthcare Asia Medtech Awards 2026",
        "url": "https://mugglehead.com/guardant-health-gets-oncology-innovation-accolade-at-healthcare-asia-medtech-awards-2026/",
        "date": "2026-04-01",
        "summary": "Guardant Health Inc. (NASDAQ: GH) (FRA: 5GH) received the Oncology Product Innovation of the Year award at the Healthcare Asia Medtech Awards 2026 for its Shield multi-cancer detection test. The award comes shortly after Guardant launched Shield in Hong Kong, Singapore, and the Philippines, partnering with Manulife to offer the test to insurance customers. The Shield test, a methylation-based blood test, screens for 10 common cancers with high specificity, improving early detection and patient o",
        "sentiment_score": 0.410522,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.881,
          "confidence": 0.88
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Guardant Health (GH) and Verana Health Announces New Partnership",
        "url": "https://www.insidermonkey.com/blog/guardant-health-gh-and-verana-health-announces-new-partnership-1727963/?amp=1",
        "date": "2026-03-31",
        "summary": "Guardant Health (NASDAQ:GH) and Verana Health have announced a new partnership to provide biopharmaceutical researchers with access to Guardant's clinicogenomic testing data and Verana's EHR datasets. This collaboration aims to accelerate the development of new therapies and improve patient care by allowing researchers to connect molecular biomarkers with treatment decisions and clinical outcomes. Guardant Health specializes in precision oncology, using data, blood-based tests, and advanced anal",
        "sentiment_score": 0.406662,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.2,
          "confidence": 0.2
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Why Is Guardant Health (GH) Stock Soaring Today",
        "url": "https://www.tradingview.com/news/stockstory:4270c6473094b:0-why-is-guardant-health-gh-stock-soaring-today/",
        "date": "2026-03-31",
        "summary": "Guardant Health (GH) stock saw a 5.9% increase after the company announced that its InfinityAI platform's real-world evidence contributed to the approval of the cancer drug ENHERTU® in Japan. This development validates Guardant's AI technology in precision oncology. Despite the recent jump, the stock remains volatile and is down 9.2% year-to-date and 21.2% below its 52-week high.",
        "sentiment_score": 0.032761,
        "sentiment_label": "Neutral",
        "relevance_score": 0.326533,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Guardant Health real-world data supports Japan approval of ENHERTU for HER2-positive tumors",
        "url": "https://www.msn.com/en-us/health/other/guardant-health-real-world-data-supports-japan-approval-of-enhertu-for-her2-positive-tumors/ar-AA1ZJdPW?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1",
        "date": "2026-03-31",
        "summary": "Guardant Health's real-world data has supported the Japan Pharmaceuticals and Medical Devices Agency's approval of ENHERTU for treating HER2-positive tumors. This approval represents a significant step forward in personalized medicine for these cancer types, leveraging genomic profiling for treatment decisions. The data likely demonstrated the effectiveness or necessity of identifying HER2 status in patients.",
        "sentiment_score": 0.623998,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.681,
          "confidence": 0.68
        }
      },
      {
        "source": "alpha_vantage",
        "title": "The Bull Case For Guardant Health (GH) Could Change Following Japan’s ENHERTU Approval Using Its AI Data",
        "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/the-bull-case-for-guardant-health-gh-could-change-following",
        "date": "2026-03-31",
        "summary": "Guardant Health's InfinityAI and Guardant360 platforms helped secure regulatory approval for Daiichi Sankyo’s ENHERTU in Japan, demonstrating the growing role of AI-driven real-world data in oncology drug approvals. While this reinforces the value of Guardant's data assets, the company still faces challenges with cash burn and achieving profitability. The approval, alongside partnerships like Verana Health, solidifies Guardant's position in AI-enabled oncology data but raises execution risks in ",
        "sentiment_score": 0.316657,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.477,
          "confidence": 0.48
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Guardant Health Inc (GH) Trading Down 3.96% on Mar 30",
        "url": "https://www.gurufocus.com/news/8756885/guardant-health-inc-gh-trading-down-396-on-mar-30?mobile=true",
        "date": "2026-03-30",
        "summary": "Guardant Health Inc (GH) experienced a 3.96% decline in its stock price on March 30, trading down to $84.61. While Wall Street analysts have an average target price of $129.67, suggesting a potential upside, GuruFocus estimates a different fair value of $67.08, implying a downside from the current price. The stock's trading volume was significantly higher than its average daily volume during this period.",
        "sentiment_score": -0.284759,
        "sentiment_label": "Somewhat-Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Guardant Health’s InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan",
        "url": "https://www.businesswire.com/news/home/20260330846159/en/Guardant-Healths-InfinityAI-Real-World-Evidence-Supports-Approval-of-ENHERTU-for-Previously-Treated-Patients-with-HER2-Positive-Metastatic-Solid-Tumors-in-Japan",
        "date": "2026-03-30",
        "summary": "Guardant Health's InfinityAI platform provided crucial real-world evidence, alongside clinical trial data, to support the recent approval of ENHERTU® in Japan. This approval, granted by Japan’s Ministry of Health, Labour and Welfare, is for treating HER2-positive metastatic solid cancers refractory to standard treatments. The collaboration with Daiichi Sankyo highlights the increasing importance of real-world data in expanding access to targeted therapies for rare biomarker-defined patient popul",
        "sentiment_score": 0.486348,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.735,
          "confidence": 0.74
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Guardant Health to present new cancer research while stock trades lower amid strong sell signals",
        "url": "https://tradersunion.com/news/companies/show/1818093-guardant-health-drops-3-96percent-today/",
        "date": "2026-03-29",
        "summary": "Guardant Health is set to present 28 abstracts at the AACR26 event, showcasing advancements in cancer diagnostics and research, particularly in methylation-based tumor classification and multiomic testing. Despite this upcoming presentation of new cancer research, the company's stock has experienced a 3.96% intraday drop, trading lower amid strong sell signals and sustained bearish momentum. Technical indicators suggest further downside risk, with the stock positioned below key moving averages a",
        "sentiment_score": -0.624824,
        "sentiment_label": "Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.511,
          "confidence": 0.51
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Guardant Health Shares Fall as Market Reacts to Conflict, Policy Deadlines | 2026 - News and Statistics",
        "url": "https://www.indexbox.io/blog/guardant-health-stock-drops-amid-market-uncertainty-and-low-consumer-confidence/",
        "date": "2026-03-28",
        "summary": "Guardant Health's stock declined in afternoon trading, reflecting broader market unease fueled by international conflict and upcoming policy deadlines. This market sentiment also pushed consumer confidence to a three-month low, and the company's shares are now trading below their year-to-date peak and are worth less than their value five years ago. The article also provides details on a report about the composite laboratory reagents industry in the United States, including market analysis, trade",
        "sentiment_score": -0.625957,
        "sentiment_label": "Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": -0.026,
          "confidence": 0.03
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Why Guardant Health (GH) Stock Is Falling Today",
        "url": "https://www.tradingview.com/news/stockstory:a4995f8d7094b:0-why-guardant-health-gh-stock-is-falling-today/",
        "date": "2026-03-27",
        "summary": "Guardant Health (GH) stock fell 3% today due to escalating uncertainty from the U.S.-Iran conflict and Trump administration policy deadlines, which also caused major indices to drop. This follows a 3.4% dip almost a month ago driven by higher-than-expected wholesale inflation data. Guardant Health's shares are highly volatile and have fallen 16.7% year-to-date, trading significantly below its 52-week high.",
        "sentiment_score": -0.395694,
        "sentiment_label": "Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.153,
          "confidence": 0.15
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Guardant Health wins at Healthcare Asia Medtech Awards 2026",
        "url": "https://healthcareasiamagazine.com/co-written-partner/event-news/guardant-health-wins-healthcare-asia-medtech-awards-2026",
        "date": "2026-03-27",
        "summary": "Guardant Health Pte Ltd won the Oncology Product Innovation of the Year at the Healthcare Asia Medtech Awards 2026 for its ShieldTM Multi-cancer Detection (MCD) test. This blood test screens for 10 types of cancers, demonstrating 99% overall specificity and 74% sensitivity across six aggressive cancers in recent data. The Shield MCD test has also received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA).",
        "sentiment_score": 0.441662,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.772,
          "confidence": 0.77
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Tempus AI Reinforces Market Position With Collaborations in 2026",
        "url": "https://www.tradingview.com/news/zacks:5e5cf70e2094b:0-tempus-ai-reinforces-market-position-with-collaborations-in-2026/",
        "date": "2026-03-26",
        "summary": "Tempus AI (TEM) is strengthening its market position in 2026 through strategic collaborations with pharmaceutical companies, healthcare institutions, and technology innovators. These partnerships aim to improve clinical outcomes and accelerate drug development by leveraging Tempus's AI expertise and proprietary platforms. Notable collaborations include work with Daiichi Sankyo on an ADC program, Median Technologies for lung nodule characterization, Blood Cancer United for a pediatric AML registr",
        "sentiment_score": 0.047954,
        "sentiment_label": "Neutral",
        "relevance_score": 0.341922,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Guardant Health (GH) partners with Manulife to launch Shield multi-cancer detection test in Asia",
        "url": "http://www.msn.com/en-us/health/other/guardant-health-gh-partners-with-manulife-to-launch-shield-multi-cancer-detection-test-in-asia/ar-AA1Z4xZA?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1",
        "date": "2026-03-25",
        "summary": "Guardant Health (GH) is partnering with Manulife to introduce its Shield multi-cancer detection test across Asia. This collaboration aims to provide enhanced cancer screening options in the region, leveraging Manulife's network to expand access to Guardant Health's diagnostic technology. The initiative represents a significant step in making advanced multi-cancer detection more widely available.",
        "sentiment_score": 0.405922,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Guardant Health Ignites 5.6% Surge: A Volatile Breakout or a Trap for the Unwary?",
        "url": "https://www.bitget.com/news/detail/12560605304566",
        "date": "2026-03-25",
        "summary": "Guardant Health (GH) experienced a 5.63% intraday surge to $89.245, driven by a new partnership with Manulife, despite technical indicators like the RSI being deeply oversold. While the rally shows short-term bullish momentum and potential for breakout past the 30-day moving average, it faces resistance around the $90 psychological barrier and requires sustained movement above $95 to confirm a trend reversal. Options traders are targeting calls with high leverage and liquidity, signaling aggress",
        "sentiment_score": 0.331999,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.318,
          "confidence": 0.32
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Cancer drug researchers gain combined patient and genomics data",
        "url": "https://www.stocktitan.net/news/GH/verana-health-and-guardant-health-partner-to-advance-precision-2sbofpkxcb3q.html",
        "date": "2026-03-24",
        "summary": "Verana Health and Guardant Health have partnered to combine Verana's EHR datasets with Guardant's clinicogenomic testing data, aiming to accelerate oncology drug development and enhance real-world treatment insights. This collaboration expands access to over 95 million patients and more than 30 academic medical centers, providing biopharmaceutical researchers with comprehensive data to understand patient journeys and validate molecular biomarkers. The partnership is expected to streamline drug d",
        "sentiment_score": 0.340597,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 0.973091,
        "sentiment": {
          "label": "negative",
          "score": -0.25,
          "confidence": 0.25
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Verana and Guardant’s RWE Stack Aims to Solve Precision Oncology’s Data Challenges—Driving Growth Through Recurring Revenue and Broader Data Collections",
        "url": "https://www.bitget.com/amp/news/detail/12560605299239",
        "date": "2026-03-24",
        "summary": "Verana Health and Guardant Health are collaborating to build a robust real-world evidence (RWE) data platform to address precision oncology's data challenges. This partnership integrates Guardant's clinicogenomic datasets with COTA's AI-enhanced oncology data, acquired through Verana's merger, to provide comprehensive insights for drug development. The strategy focuses on high-margin, recurring revenue streams from companion diagnostics and expanding into new therapeutic areas like bladder and p",
        "sentiment_score": 0.04722,
        "sentiment_label": "Neutral",
        "relevance_score": 0.335742,
        "sentiment": {
          "label": "positive",
          "score": 0.527,
          "confidence": 0.53
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Verana Health and Guardant Health Partner to Advance Precision Medicine with Real-World Data",
        "url": "https://www.prnewswire.com/news-releases/verana-health-and-guardant-health-partner-to-advance-precision-medicine-with-real-world-data-302719285.html",
        "date": "2026-03-24",
        "summary": "Verana Health and Guardant Health have partnered to combine their real-world data resources to accelerate precision medicine, particularly in oncology and urology. This collaboration will allow biopharmaceutical researchers to access curated EHR data alongside clinicogenomic testing data, enhancing the understanding of patient journeys and aiding therapy development. The combined data sets will help validate correlations between molecular biomarkers, treatment decisions, and clinical outcomes, a",
        "sentiment_score": 0.443171,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Guardant Health (GH) director’s RSU vesting adds 264 common shares",
        "url": "https://www.stocktitan.net/sec-filings/GH/form-4-guardant-health-inc-insider-trading-activity-5b119b371c3f.html",
        "date": "2026-03-24",
        "summary": "Guardant Health director Roberto Mignone reported the vesting and settlement of 264 restricted stock units (RSUs) into common shares. This transaction, part of a routine equity compensation event, increased his direct holdings to 4,487 common shares and 8,184 RSUs. The vested RSUs are from an award granted on November 8, 2024, with a vesting schedule of 25% on the one-year anniversary and the remainder monthly over three years.",
        "sentiment_score": 0.044964,
        "sentiment_label": "Neutral",
        "relevance_score": 0.312896,
        "sentiment": {
          "label": "positive",
          "score": 0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Guardant Health (GH) Valuation Check As New Manulife Partnership Expands Shield Testing In Asia",
        "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/guardant-health-gh-valuation-check-as-new-manulife-partnersh",
        "date": "2026-03-23",
        "summary": "Guardant Health (GH) is under scrutiny after announcing a partnership with Manulife to expand its Shield multi-cancer detection blood test in Asia, starting April 2026. Despite recent share price volatility, the company has shown strong long-term momentum with an 84.77% one-year return, yet some models suggest it's significantly undervalued. The article debates whether the market has already factored in future growth, highlighting potential valuation risks from a high P/S ratio compared to the i",
        "sentiment_score": 0.253613,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.303,
          "confidence": 0.3
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Guardant Health (GH) partners with Manulife to launch Shield multi-cancer detection test in Asia",
        "url": "https://www.msn.com/en-us/health/other/guardant-health-gh-partners-with-manulife-to-launch-shield-multi-cancer-detection-test-in-asia/ar-AA1Z4xZA",
        "date": "2026-03-22",
        "summary": "Guardant Health (GH) has partnered with Manulife to introduce its Shield multi-cancer detection test in Asia. This collaboration aims to provide early cancer detection solutions to a broader population in the region through Manulife's network. The Shield test is designed to detect multiple types of cancer at early stages, potentially improving patient outcomes.",
        "sentiment_score": 0.422472,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Why Guardant Health’s (GH) 2026 screening story reinforced Piper Sandler’s bullish view",
        "url": "https://www.msn.com/en-us/money/companies/why-guardant-health-s-gh-2026-screening-story-reinforced-piper-sandler-s-bullish-view/ar-AA1YTUKn?ocid=finance-verthp-feeds",
        "date": "2026-03-21",
        "summary": "This article discusses Piper Sandler's maintained bullish outlook on Guardant Health (GH), specifically reinforced by insights from the company's 2026 screening strategy. The analyst firm highlighted a conference presentation that detailed key upcoming milestones and reiterated confidence in Guardant Health's future growth prospects.",
        "sentiment_score": 0.847813,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Guardant Health (GH) partners with Manulife to launch Shield multi-cancer detection test in Asia",
        "url": "https://www.msn.com/en-us/money/general/guardant-health-gh-partners-with-manulife-to-launch-shield-multi-cancer-detection-test-in-asia/ar-AA1Z4xZA",
        "date": "2026-03-21",
        "summary": "Guardant Health (GH) has partnered with Manulife to launch its Shield multi-cancer detection test in Asia. This collaboration aims to make the early cancer detection test accessible to a broader population in the region, leveraging Manulife's network. The Shield test is designed to detect multiple types of cancer from a single blood draw.",
        "sentiment_score": 0.422818,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Insider Sell: Musa Tariq Sells Shares of Guardant Health Inc (GH)",
        "url": "https://www.gurufocus.com/news/8728137/insider-sell-musa-tariq-sells-shares-of-guardant-health-inc-gh",
        "date": "2026-03-20",
        "summary": "Musa Tariq, a Director at Guardant Health Inc (GH), sold 348 shares of the company on March 18, 2026, bringing his total ownership to 8,394 shares. Over the past year, Tariq has sold a total of 4,489 shares with no purchases. Guardant Health Inc is considered significantly overvalued with a price-to-GF-Value ratio of 1.68, based on its trading price of $88.09 against a GF Value of $52.52.",
        "sentiment_score": -0.31548,
        "sentiment_label": "Somewhat-Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Insider Selling: Guardant Health (NASDAQ:GH) Director Sells 348 Shares of Stock",
        "url": "https://www.marketbeat.com/instant-alerts/insider-selling-guardant-health-nasdaqgh-director-sells-348-shares-of-stock-2026-03-19/",
        "date": "2026-03-19",
        "summary": "Guardant Health (NASDAQ:GH) Director Musa Tariq sold 348 shares of the company's stock on March 18, 2026, for a total value of $30,655.32. This sale reduced his stake by 3.98% to 8,394 shares. The company's stock traded up 2.1% to $89.08, and despite missing Q4 EPS estimates, revenue increased by 39.4% year-over-year.",
        "sentiment_score": -0.193474,
        "sentiment_label": "Somewhat-Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Guardant Health (NASDAQ: GH) director sells 348 company shares",
        "url": "https://www.stocktitan.net/sec-filings/GH/form-4-guardant-health-inc-insider-trading-activity-426fc16d4cb8.html",
        "date": "2026-03-19",
        "summary": "Guardant Health director Tariq Musa sold 348 shares of the company's common stock on March 18, 2026, at an average price of $88.09 per share. This open-market transaction was reported via a Form 4 SEC filing. Following the sale, Musa directly holds 8,394 shares of Guardant Health stock.",
        "sentiment_score": -0.270047,
        "sentiment_label": "Somewhat-Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Guardant Health (GH) director Tariq Musa sells $30,655 in stock",
        "url": "https://m.investing.com/news/insider-trading-news/guardant-health-gh-director-tariq-musa-sells-30655-in-stock-93CH-4571897?ampMode=1",
        "date": "2026-03-19",
        "summary": "Guardant Health (GH) director Tariq Musa sold 348 shares of common stock for $30,655 on March 18, 2026, bringing his total direct ownership to 8,394 shares. This insider sale occurs as the company's stock trades near $89.08. Separately, Guardant Health recently reported its Q4 2025 results, with several analysts reaffirming or increasing price targets due to strong performance and a positive outlook for commercial expansion and cost management.",
        "sentiment_score": 0.105383,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Cathie Wood’s ARK sells Guardant Health stock, buys Arcturus Therapeutics",
        "url": "https://www.investing.com/news/company-news/cathie-woods-ark-sells-guardant-health-stock-buys-arcturus-therapeutics-93CH-4569651",
        "date": "2026-03-19",
        "summary": "Cathie Wood's ARK sold 11,757 shares of Guardant Health (NASDAQ:GH) totaling over $1 million through its ARKG ETF, continuing a trend of reducing its position in the company. Concurrently, ARK purchased 33,864 shares of Arcturus Therapeutics Holdings (NASDAQ:ARCT) for $216,390, indicating a strategic shift towards innovative therapeutics. A smaller sale of Standard Biotools (NASDAQ:LAB) shares also occurred, reflecting ARK's ongoing portfolio reallocation within the biotech sector.",
        "sentiment_score": -0.394566,
        "sentiment_label": "Bearish",
        "relevance_score": 0.969669,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Director at Guardant Health (GH) receives 232 shares via RSUs",
        "url": "https://www.stocktitan.net/sec-filings/GH/form-4-guardant-health-inc-insider-trading-activity-5d6041acaa59.html",
        "date": "2026-03-18",
        "summary": "Guardant Health director Manuel Hidalgo Medina received 232 common shares through the exercise of restricted stock units (RSUs) on March 17, 2026, as part of his equity compensation. These shares were converted at a price of $0.00 per share, increasing his direct holdings to 1,425 shares. The RSU award originated from a grant on July 17, 2024, with a four-year vesting schedule.",
        "sentiment_score": 0.000682,
        "sentiment_label": "Neutral",
        "relevance_score": 0.322116,
        "sentiment": {
          "label": "positive",
          "score": 0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Guardant Health (NASDAQ: GH) Form 144 shows proposed insider sale of shares",
        "url": "https://www.stocktitan.net/sec-filings/GH/144-guardant-health-inc-sec-filing-295c113b5a16.html",
        "date": "2026-03-18",
        "summary": "Guardant Health (NASDAQ: GH) has filed a Form 144 indicating proposed insider sales of shares. The filing details planned dispositions of Common Stock linked to restricted stock lapses, with events scheduled for January 15, 2026 (250 shares) and February 15, 2026 (98 shares), handled by Charles Schwab & Co., Inc. This notice acts as a procedural disclosure of intent to sell rather than a record of completed transactions.",
        "sentiment_score": 0.030597,
        "sentiment_label": "Neutral",
        "relevance_score": 0.951167,
        "sentiment": {
          "label": "positive",
          "score": 0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Guardant Health Launches Shield Multi-Cancer Detection (MCD) Test in Multiple Markets in Asia with Manulife Partnership",
        "url": "https://www.businesswire.com/news/home/20260316025112/en/Guardant-Health-Launches-Shield-Multi-Cancer-Detection-MCD-Test-in-Multiple-Markets-in-Asia-with-Manulife-Partnership",
        "date": "2026-03-18",
        "summary": "Guardant Health, Inc. announced the launch of its Shield multi-cancer detection (MCD) test in several Asian markets through a partnership with Manulife. This collaboration will provide eligible Manulife customers in Hong Kong, Singapore, and the Philippines access to the blood-based test, which screens for 10 common cancers, starting in April 2026. The initiative aims to improve early cancer detection and screening participation in a region where cancer remains a leading cause of death.",
        "sentiment_score": 0.407843,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.2,
          "confidence": 0.2
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Guardant Health to Present 28 Abstracts Highlighting Advances in Tumor Typing, Therapy Selection and Expanded Utility of Multiomic Tissue and Liquid Biopsy Testing at AACR 2026",
        "url": "https://www.biospace.com/press-releases/guardant-health-to-present-28-abstracts-highlighting-advances-in-tumor-typing-therapy-selection-and-expanded-utility-of-multiomic-tissue-and-liquid-biopsy-testing-at-aacr-2026",
        "date": "2026-03-18",
        "summary": "Guardant Health and its collaborators will present 28 abstracts, including 3 oral sessions, at the AACR Annual Meeting in April 2026. The presentations will showcase advances in methylation-based tumor classification and liquid biopsy technology, highlighting the utility of Guardant360 Tissue and Guardant360 Liquid in tumor typing and therapy selection. Key data includes high accuracy of Guardant360 Tissue in determining tissue of origin and expanded clinical actionability of Guardant360 Liquid,",
        "sentiment_score": 0.470056,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.382,
          "confidence": 0.38
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Blood tests flag new primary cancers and actionable results in AACR data",
        "url": "https://www.stocktitan.net/news/GH/guardant-health-to-present-28-abstracts-highlighting-advances-in-bapvicsrazan.html",
        "date": "2026-03-18",
        "summary": "Guardant Health will present 28 abstracts at the American Association for Cancer Research (AACR) Annual Meeting in April 2026, highlighting advances in its liquid biopsy technology. Key findings include the high accuracy of Guardant360 Tissue in determining cancer origin, the expanded utility of Guardant360 Liquid in identifying actionable findings for breast and colorectal cancer patients, and Guardant Reveal's potential to detect new primary malignancies during minimal residual disease monitor",
        "sentiment_score": 0.343759,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Guardant Health (NASDAQ:GH) CFO Sells $261,120.00 in Stock",
        "url": "https://www.marketbeat.com/instant-alerts/guardant-health-nasdaqgh-cfo-sells-26112000-in-stock-2026-03-17/",
        "date": "2026-03-18",
        "summary": "Guardant Health (NASDAQ:GH) CFO Michael Brian Bell sold 3,000 shares of the company's stock for $261,120.00 on March 16, 2026, reducing his stake by 6.44%. The company recently missed EPS expectations in its latest earnings report but exceeded revenue estimates. Guardant Health stock traded at $88.75 mid-day, below its 50-day and 200-day simple moving averages, and institutional investors own approximately 92.6% of the outstanding shares.",
        "sentiment_score": 0.034052,
        "sentiment_label": "Neutral",
        "relevance_score": 0.33154,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Guardant Health (NASDAQ: GH) CLO gains stock through RSU vesting",
        "url": "https://www.stocktitan.net/sec-filings/GH/form-4-guardant-health-inc-insider-trading-activity-4dd8254703cb.html",
        "date": "2026-03-17",
        "summary": "Guardant Health's Chief Legal Officer, John G. Saia, acquired additional common stock through the vesting of performance-based and time-based Restricted Stock Units (RSUs) on March 15, 2026. After the transactions, and accounting for shares withheld for tax obligations, Mr. Saia directly owns 56,903 shares of Guardant Health common stock. The filing details how 4,622 shares were retained by the company at $85.49 per share to cover tax withholdings related to the RSU vesting.",
        "sentiment_score": 0.015433,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.34,
          "confidence": 0.34
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Guardant Health (GH) director acquires 249 shares via RSU vesting",
        "url": "https://www.stocktitan.net/sec-filings/GH/form-4-guardant-health-inc-insider-trading-activity-78f740c8c862.html",
        "date": "2026-03-17",
        "summary": "Guardant Health director Tariq Musa converted 249 restricted stock units (RSUs) into common stock on March 15, 2026, as part of a scheduled vesting. This transaction increased his direct holdings to 8,742 common shares, with an additional 2,999 RSUs remaining. The RSUs, granted on March 6, 2023, vest over four years, with 25% vesting on the first anniversary and the rest monthly over the subsequent three years.",
        "sentiment_score": 0.038712,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Survey Supports Blood Tests for Colorectal Cancer Screening",
        "url": "https://www.curetoday.com/view/survey-supports-blood-tests-for-colorectal-cancer-screening",
        "date": "2026-03-17",
        "summary": "A new national survey indicates that 92% of adults eligible for colorectal cancer screening believe blood-based tests should be widely accessible and covered by insurance. These tests could significantly increase screening participation, with 77% of respondents stating they would be less likely to delay screening if a blood test were available. The survey highlights that blood tests could serve as a crucial entry point to screening, potentially overcoming common barriers associated with traditio",
        "sentiment_score": 0.448086,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.44,
          "confidence": 0.44
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Here’s Why Artisan Small Cap Fund Bets on Guardant Health (GH)",
        "url": "https://www.insidermonkey.com/blog/heres-why-artisan-small-cap-fund-bets-on-guardant-health-gh-1718418/",
        "date": "2026-03-17",
        "summary": "Artisan Small Cap Fund highlighted its new position in Guardant Health, Inc. (NASDAQ: GH) in its Q4 2025 investor letter. Guardant Health specializes in liquid biopsy diagnostics for cancer detection and monitoring. Despite the fund's investment, Insider Monkey suggests that some AI stocks offer greater potential for higher and faster returns than Guardant Health.",
        "sentiment_score": 0.412742,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Guardant Health launches Shield Multi-Cancer Detection Test in APAC market",
        "url": "https://www.biospectrumasia.com/news/54/27363/guardant-health-launches-shield-multi-cancer-detection-test-in-apac-market.html",
        "date": "2026-03-17",
        "summary": "Guardant Health has launched its Shield multi-cancer detection (MCD) laboratory developed test (LDT) in key Asian markets including Hong Kong, Singapore, and the Philippines, starting April 2026. This blood test screens for 10 common cancers in average-risk individuals aged 45 or older. The initiative is supported by a partnership with Manulife, aiming to enhance early cancer detection access in the region.",
        "sentiment_score": 0.450843,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Guardant Health launches multi-cancer blood test in Asia through Manulife partnership",
        "url": "https://mugglehead.com/guardant-health-launches-multi-cancer-blood-test-in-asia-through-manulife-partnership/",
        "date": "2026-03-17",
        "summary": "Guardant Health (NASDAQ: GH) has launched its Shield multi-cancer detection blood test in several Asian markets through a partnership with Manulife Financial Corporation (TSE: MFC). The test, aimed at individuals aged 45 and older, screens for 10 common cancers using a blood sample. This expansion into Hong Kong, Singapore, and the Philippines, starting in April 2026, aims to improve early cancer detection rates in regions where cancer remains a leading cause of death.",
        "sentiment_score": 0.45329,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.2,
          "confidence": 0.2
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Singapore's Guardant Health launches Shield Multi-Cancer Detection (MCD) Test in APAC market",
        "url": "https://www.biospectrumasia.com/news/26/27363/singaporesguardant-health-launches-shield-multi-cancer-detection-mcd-test-in-apac-market.html",
        "date": "2026-03-17",
        "summary": "Guardant Health has launched its Shield multi-cancer detection (MCD) test in several Asian markets including Hong Kong, Singapore, and the Philippines, starting April 2026. This blood test screens for 10 common cancers in individuals aged 45 or older and aims to enhance early detection and screening participation in the APAC region. The initiative includes a partnership with Manulife, marking a significant step in making innovative early cancer detection technologies accessible.",
        "sentiment_score": 0.630397,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Blood test that screens for 10 cancers to reach Manulife customers in Asia",
        "url": "https://www.stocktitan.net/news/GH/guardant-health-launches-shield-multi-cancer-detection-mcd-test-in-0eb8oecxpwvf.html",
        "date": "2026-03-16",
        "summary": "Guardant Health has launched its Shield multi-cancer detection (MCD) blood test in several Asian markets through a partnership with Manulife. This methylation-based test screens for 10 common cancer types in individuals aged 45 or older, with access for eligible Manulife customers in Hong Kong, Singapore, and the Philippines beginning in April 2026. The collaboration aims to expand early cancer detection in a region where cancer remains a leading cause of death.",
        "sentiment_score": 0.499069,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.026,
          "confidence": 0.03
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Guardant Health Launches Shield Multi-Cancer Detection (MCD) Test in Multiple Markets in Asia with Manulife Partnership",
        "url": "https://finance.yahoo.com/news/guardant-health-launches-shield-multi-120500633.html",
        "date": "2026-03-16",
        "summary": "Guardant Health has partnered with Manulife to launch its Shield Multi-Cancer Detection (MCD) test in several Asian markets, including Hong Kong, Singapore, and the Philippines. This collaboration allows eligible Manulife customers to access the blood-based test, which screens for 10 common cancers in individuals aged 45 or older. The initiative aims to enhance early cancer detection efforts in a region where cancer remains a leading cause of death.",
        "sentiment_score": 0.481382,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.2,
          "confidence": 0.2
        }
      },
      {
        "source": "alpha_vantage",
        "title": "HighVista Strategies LLC Acquires 36,318 Shares of Guardant Health, Inc. $GH",
        "url": "https://www.marketbeat.com/instant-alerts/filing-highvista-strategies-llc-acquires-36318-shares-of-guardant-health-inc-gh-2026-03-16/",
        "date": "2026-03-16",
        "summary": "HighVista Strategies LLC significantly increased its stake in Guardant Health by 128.5% in the third quarter, acquiring 36,318 additional shares. Despite insiders selling over 20,000 shares, institutional investors now own 92.60% of the company's stock. Guardant Health missed EPS estimates but exceeded revenue expectations, and analysts maintain a \"Moderate Buy\" rating with an average target price of $122.57.",
        "sentiment_score": 0.114428,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Fred Alger Management LLC Has $39.89 Million Holdings in Guardant Health, Inc. $GH",
        "url": "https://www.marketbeat.com/instant-alerts/filing-fred-alger-management-llc-has-3989-million-holdings-in-guardant-health-inc-gh-2026-03-16/",
        "date": "2026-03-16",
        "summary": "Fred Alger Management LLC significantly increased its stake in Guardant Health, Inc. (NASDAQ:GH) by 70.9% in the third quarter, now owning 638,487 shares valued at $39.89 million. Despite beating revenue expectations, Guardant Health missed EPS estimates in its latest quarterly report. Analysts largely maintain a bullish outlook on the company, with an average price target of $122.57, though recent insider transactions show both sales and director ownership changes.",
        "sentiment_score": 0.242187,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 0.950957,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Is Guardant Health’s (GH) Shield Tour Redefining Its Competitive Moat in Cancer Screening?",
        "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/is-guardant-healths-gh-shield-tour-redefining-its-competitiv",
        "date": "2026-03-16",
        "summary": "Guardant Health has launched its \"Shield Across America\" tour to expand the reach of its FDA-approved Shield blood test for colorectal cancer screening, targeting underserved areas and eligible adults. This initiative, supported by new NCCN guidelines and public payer coverage, aims to overcome screening barriers and increase test usage. While the tour reinforces Guardant's investment thesis, the company faces continued risks associated with high cash burn and the long path to profitability desp",
        "sentiment_score": 0.135144,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.572,
          "confidence": 0.57
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Eventide Asset Management LLC Lowers Holdings in Guardant Health, Inc. $GH",
        "url": "https://www.marketbeat.com/instant-alerts/filing-eventide-asset-management-llc-lowers-holdings-in-guardant-health-inc-gh-2026-03-15/",
        "date": "2026-03-15",
        "summary": "Eventide Asset Management LLC reduced its stake in Guardant Health, Inc. (NASDAQ:GH) by 4.0% in the third quarter, though it remains its largest holding. Despite this reduction and insider selling, Wall Street analysts largely maintain a \"Moderate Buy\" rating with an average price target of $122.57. Guardant Health recently missed EPS expectations but saw strong revenue growth, with institutional investors owning a significant portion of its stock.",
        "sentiment_score": -0.106026,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.25,
          "confidence": 0.25
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Cinctive Capital Management LP Buys Shares of 121,130 Guardant Health, Inc. $GH",
        "url": "https://www.marketbeat.com/instant-alerts/filing-cinctive-capital-management-lp-buys-shares-of-121130-guardant-health-inc-gh-2026-03-15/",
        "date": "2026-03-15",
        "summary": "Cinctive Capital Management LP acquired a new position of 121,130 shares in Guardant Health, Inc. (NASDAQ:GH) during the third quarter, valued at approximately $7.57 million. This purchase represents about 0.10% of Guardant Health's stock. Despite significant insider selling totaling $12.2 million in the last quarter, including a substantial sale by CEO Helmy Eltoukhy, the company reported Q4 revenue of $281.3 million, beating expectations with a 39.4% year-over-year increase, though EPS missed ",
        "sentiment_score": 0.122349,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Guardant Health (GH) Valuation Check As Shield Across America Expands Colorectal Cancer Screening Reach",
        "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/guardant-health-gh-valuation-check-as-shield-across-america",
        "date": "2026-03-14",
        "summary": "Guardant Health (GH) recently launched \"Shield Across America,\" a mobile screening tour for its colorectal cancer blood test, Shield, amidst a 20.53% decline in its 30-day share price but a strong 99.32% 1-year return. Despite short-term price drops, the company's valuation narrative suggests it's 35.5% undervalued at $132.57 per share compared to its current $85.49, driven by significant regulatory and clinical milestones for Shield that promise future revenue growth. However, investors are cau",
        "sentiment_score": 0.391964,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.599,
          "confidence": 0.6
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Guardant Health (GH) awards 17,040 RSUs to Chief People Officer Monroe",
        "url": "https://www.stocktitan.net/sec-filings/GH/form-4-guardant-health-inc-insider-trading-activity-e69d05dc36b9.html",
        "date": "2026-03-14",
        "summary": "Guardant Health (GH) has granted 17,040 Restricted Stock Units (RSUs) to its Chief People Officer, Terilyn J. Monroe, on March 11, 2026. These RSUs are part of a routine equity compensation award, not an open-market transaction. The RSUs will vest over a three-year period, with 33% vesting on April 1, 2027, and the remainder vesting in equal quarterly installments over the subsequent two years.",
        "sentiment_score": 0.00185,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.459,
          "confidence": 0.46
        }
      },
      {
        "source": "news",
        "source_name": "Thechronicle.com.gh",
        "title": "Politics Halts Rice, Maize Distribution –Agric Ministry Tells PAC",
        "description": "Proceedings of the Public Accounts Committee (PAC) of Parliament have revealed that political interference disrupted the execution of a major government grain distribution programme, preventing a contracted logistics firm from carrying out its mandate. Offici…",
        "url": "https://thechronicle.com.gh/politics-halts-rice-maize-distribution-agric-ministry-tells-pac/",
        "date": "2026-04-01",
        "published_at": "2026-04-01T02:07:17Z",
        "sentiment": {
          "label": "neutral",
          "score": -0.026,
          "confidence": 0.03
        }
      },
      {
        "source": "news",
        "source_name": "Thechronicle.com.gh",
        "title": "Nsein chief gives Lower Axim counter three-month ultimatum to vacate his land",
        "description": "A festering chieftaincy dispute between two paramount stools in Western Region has escalated sharply, raising fears of violence if urgent intervention is not secured. At the centre of the impasse are the Paramount Chief of Nsein, Awulae Agyefi Kwame, and the …",
        "url": "https://thechronicle.com.gh/nsein-chief-gives-lower-axim-counter-three-month-ultimatum-to-vacate-his-land/",
        "date": "2026-04-01",
        "published_at": "2026-04-01T01:00:53Z",
        "sentiment": {
          "label": "negative",
          "score": -0.905,
          "confidence": 0.91
        }
      },
      {
        "source": "news",
        "source_name": "Github.com",
        "title": "Show HN: Initialize an AI Harness with Forge CLI",
        "description": "AI agent pipeline scaffolding CLI — detects stack, renders CLAUDE.md, agents, hooks, pipeline scripts, and compliance addons - samahlstrom/forge-cli",
        "url": "https://github.com/samahlstrom/forge-cli",
        "date": "2026-03-31",
        "published_at": "2026-03-31T23:24:44Z",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "news",
        "source_name": "Github.com",
        "title": "Show HN: King Louie a local multi-machine AI assistant",
        "description": "Article URL: https://github.com/the-banana-tool/king-louie\nComments URL: https://news.ycombinator.com/item?id=47593640\nPoints: 1\n# Comments: 0",
        "url": "https://github.com/the-banana-tool/king-louie",
        "date": "2026-03-31",
        "published_at": "2026-03-31T21:23:33Z",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "news",
        "source_name": "Anime News Network",
        "title": "Hosana Tanaka's Megami no Ko Manga Ends With 3rd Volume",
        "description": "Manga ended serialization in November, final volume shipped on Monday",
        "url": "https://www.animenewsnetwork.com/news/2026-03-31/hosana-tanaka-megami-no-ko-manga-ends-with-3rd-volume/.235991",
        "date": "2026-03-31",
        "published_at": "2026-03-31T21:00:00Z",
        "sentiment": {
          "label": "negative",
          "score": -0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "news",
        "source_name": "Pypi.org",
        "title": "deepdoc 0.1.1",
        "description": "Auto-generate beautiful docs from any codebase",
        "url": "https://pypi.org/project/deepdoc/",
        "date": "2026-03-31",
        "published_at": "2026-03-31T19:59:23Z",
        "sentiment": {
          "label": "positive",
          "score": 0.599,
          "confidence": 0.6
        }
      },
      {
        "source": "news",
        "source_name": "Pypi.org",
        "title": "gh-audit 0.1.3",
        "description": "GitHub audit, governance, and inventory for organizations",
        "url": "https://pypi.org/project/gh-audit/0.1.3/",
        "date": "2026-03-31",
        "published_at": "2026-03-31T19:51:32Z",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "news",
        "source_name": "Pypi.org",
        "title": "gh-audit 0.1.2",
        "description": "GitHub audit, governance, and inventory for organizations",
        "url": "https://pypi.org/project/gh-audit/0.1.2/",
        "date": "2026-03-31",
        "published_at": "2026-03-31T19:09:09Z",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "news",
        "source_name": "Pypi.org",
        "title": "gh-audit added to PyPI",
        "description": "GitHub audit, governance, and inventory for organizations",
        "url": "https://pypi.org/project/gh-audit/",
        "date": "2026-03-31",
        "published_at": "2026-03-31T19:09:05Z",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "news",
        "source_name": "Yahoo Entertainment",
        "title": "Guardant Health (GH) and Verana Health Announces New Partnership",
        "description": "",
        "url": "https://consent.yahoo.com/v2/collectConsent?sessionId=1_cc-session_eddc6600-b47b-4adb-920c-3402b82dbd0c",
        "date": "2026-03-31",
        "published_at": "2026-03-31T15:06:18Z",
        "sentiment": {
          "label": "positive",
          "score": 0.2,
          "confidence": 0.2
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "Precision Medicine Software Market Outlook 2026-2030 & 2035 - Philips, Palantir Technologies, and Tempus Labs Lead the $2.82 Billion Industry",
        "description": "Growth is fueled by advancements in genomic technologies, rising precision oncology, and focus on interoperable healthcare systems Growth is fueled by advancements in genomic technologies, rising precision oncology, and focus on interoperable healthcare syste…",
        "url": "https://www.globenewswire.com/news-release/2026/03/31/3265764/28124/en/Precision-Medicine-Software-Market-Outlook-2026-2030-2035-Philips-Palantir-Technologies-and-Tempus-Labs-Lead-the-2-82-Billion-Industry.html",
        "date": "2026-03-31",
        "published_at": "2026-03-31T15:04:00Z",
        "sentiment": {
          "label": "positive",
          "score": 0.637,
          "confidence": 0.64
        }
      },
      {
        "source": "news",
        "source_name": "Plos.org",
        "title": "Biobanking of gynecologic cancer biospecimens: Development, quality control, and translational applications",
        "description": "Introduction This study presents a nationwide infrastructure for the collection and utilization of gynecologic cancer biospecimens, established through the Korea Biobank Project. We comprehensively describe the biobanking strategy, quality control protocols, …",
        "url": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0345861",
        "date": "2026-03-31",
        "published_at": "2026-03-31T14:00:00Z",
        "sentiment": {
          "label": "negative",
          "score": -0.869,
          "confidence": 0.87
        }
      },
      {
        "source": "news",
        "source_name": "Plos.org",
        "title": "The adapt-to-nutrient NRPS-like secondary metabolite gene cluster facilitates Verticillium dahliae adaptation to different nutrient environments",
        "description": "Author summary Verticillium dahliae is an economically significant phytopathogen that is widely distributed. The fungus adjusts and adapts its survival strategy according to the surrounding environment. Transcriptome data revealed that the core biosynthetic g…",
        "url": "https://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1011930",
        "date": "2026-03-31",
        "published_at": "2026-03-31T14:00:00Z",
        "sentiment": {
          "label": "positive",
          "score": 0.202,
          "confidence": 0.2
        }
      },
      {
        "source": "news",
        "source_name": "Plos.org",
        "title": "Determination of factors that allow cryogenic nanoscopy with high power illumination without devitrification",
        "description": "Cryogenic fluorescence nanoscopy, also known as super-resolution fluorescence light microscopy, has been demonstrated to be useful to close the resolution gap in cryogenic correlative light and electron microscopy (CLEM). Importantly, under cryogenic conditio…",
        "url": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0344631",
        "date": "2026-03-31",
        "published_at": "2026-03-31T14:00:00Z",
        "sentiment": {
          "label": "positive",
          "score": 0.832,
          "confidence": 0.83
        }
      },
      {
        "source": "news",
        "source_name": "Plos.org",
        "title": "New Histone H4 variant and H2B variant Exhibits distinct genomic distributions, chromatin affinities, and dynamics throughout life and cell cycle of Trypanosoma cruzi",
        "description": "Author summary Chromatin is composed of a group of proteins called histones that are involved in compacting DNA and thereby affecting many DNA-associated mechanisms, such as replication and transcription. Histone variants share distinct primary sequences from…",
        "url": "https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1013310",
        "date": "2026-03-31",
        "published_at": "2026-03-31T14:00:00Z",
        "sentiment": {
          "label": "positive",
          "score": 0.511,
          "confidence": 0.51
        }
      },
      {
        "source": "news",
        "source_name": "Github.com",
        "title": "Show HN: \"Have your LLM talk to my LLM\"",
        "description": "Article URL: https://github.com/dvelton/rendezvous\nComments URL: https://news.ycombinator.com/item?id=47587094\nPoints: 1\n# Comments: 1",
        "url": "https://github.com/dvelton/rendezvous",
        "date": "2026-03-31",
        "published_at": "2026-03-31T13:30:31Z",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "news",
        "source_name": "Pypi.org",
        "title": "json-object-mapper added to PyPI",
        "description": "Attribute-style access wrapper for JSON-like data with dot-path set/delete and safe defaults",
        "url": "https://pypi.org/project/json-object-mapper/",
        "date": "2026-03-31",
        "published_at": "2026-03-31T10:09:56Z",
        "sentiment": {
          "label": "positive",
          "score": 0.44,
          "confidence": 0.44
        }
      },
      {
        "source": "news",
        "source_name": "Github.com",
        "title": "Show HN: HolyCode – OpenCode in Docker. Use your Claude subscription. 30 tools",
        "description": "HolyCode is a Docker image that wraps OpenCode (https://opencode.ai), an AI coding agent with a web UI. It ships with 30+ dev tools pre-installed, a headless Chromium/Xvfb/Playwright stack, s6-overlay for process supervision, and UID/GID remapping for correct…",
        "url": "https://github.com/CoderLuii/HolyCode",
        "date": "2026-03-31",
        "published_at": "2026-03-31T08:29:46Z",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "news",
        "source_name": "Thechronicle.com.gh",
        "title": "Heath Goldfields Has Brought Renewed Hope To Prestea-Bogoso -Group",
        "description": "Hope has been rekindled in the Prestea-Bogoso enclave following the rapid revival of mining operations by Heath Goldfields, with residents and stakeholders calling on government to safeguard the company’s growing investment. At a press conference held yesterd…",
        "url": "https://thechronicle.com.gh/heath-goldfields-has-brought-renewed-hope-to-prestea-bogoso-group/",
        "date": "2026-03-31",
        "published_at": "2026-03-31T08:04:42Z",
        "sentiment": {
          "label": "positive",
          "score": 0.844,
          "confidence": 0.84
        }
      },
      {
        "source": "news",
        "source_name": "Thechronicle.com.gh",
        "title": "Tarkwa Court Remands Two Students Over Supermarket Break-In and Theft",
        "description": "The Circuit Court in Tarkwa has remanded two young men, including a student of Takoradi Technical University, into custody for allegedly stealing cash and goods from a local supermarket. The accused, Kingsford Quarshie, also known as “Cash Money,” 21, a miner…",
        "url": "https://thechronicle.com.gh/tarkwa-court-remands-two-students-over-supermarket-break-in-and-theft/",
        "date": "2026-03-31",
        "published_at": "2026-03-31T07:56:13Z",
        "sentiment": {
          "label": "negative",
          "score": -0.71,
          "confidence": 0.71
        }
      },
      {
        "source": "news",
        "source_name": "Droppedasbaby.com",
        "title": "Accidentally created my first fork bomb with Claude Code",
        "description": "Accidentally created my first fork bomb with Claude Code, bricked my computer overnight, and somehow built useful tools along the way.",
        "url": "https://www.droppedasbaby.com/posts/2602-01/",
        "date": "2026-03-31",
        "published_at": "2026-03-31T07:40:18Z",
        "sentiment": {
          "label": "negative",
          "score": -0.649,
          "confidence": 0.65
        }
      },
      {
        "source": "news",
        "source_name": "Github.com",
        "title": "Show HN: Claudebase: Sync your Claude Code env across machines via GitHub",
        "description": "Article URL: https://github.com/rohithzr/claudebase\nComments URL: https://news.ycombinator.com/item?id=47583664\nPoints: 1\n# Comments: 0",
        "url": "https://github.com/rohithzr/claudebase",
        "date": "2026-03-31",
        "published_at": "2026-03-31T06:53:23Z",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "news",
        "source_name": "Pypi.org",
        "title": "deathstar-ai added to PyPI",
        "description": "Secure AWS-hosted remote AI coding workstation with a provider-agnostic local CLI.",
        "url": "https://pypi.org/project/deathstar-ai/",
        "date": "2026-03-31",
        "published_at": "2026-03-31T06:15:04Z",
        "sentiment": {
          "label": "positive",
          "score": 0.34,
          "confidence": 0.34
        }
      },
      {
        "source": "news",
        "source_name": "ComingSoon.net",
        "title": "Sofia Mattsson’s New Soap Casting Revealed After General Hospital Exit",
        "description": "Sofia Mattsson is making a dramatic move after her seven-year stint as Sasha Gilmore on General Hospital. After exiting the ABC drama, Mattsson has been busy preparing for her next chapter. With her extensive experience in daytime drama, the Swedish-born actr…",
        "url": "https://www.comingsoon.net/tv/news/2114104-sofia-mattsson-cast-days-of-our-lives-general-hospital",
        "date": "2026-03-31",
        "published_at": "2026-03-31T05:56:58Z",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "news",
        "source_name": "Github.com",
        "title": "Agent-Reach - Give your AI agent eyes to see the entire internet",
        "description": "Give your AI agent eyes to see the entire internet. Read & search Twitter, Reddit, YouTube, GitHub, Bilibili, XiaoHongShu — one CLI, zero API fees. - Panniantong/Agent-Reach",
        "url": "https://github.com/Panniantong/Agent-Reach",
        "date": "2026-03-31",
        "published_at": "2026-03-31T05:47:01Z",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "news",
        "source_name": "Deadline",
        "title": "Sofia Mattsson Joins ‘Days Of Our Lives’ Following ‘General Hospital’ Departure",
        "description": "Salem is getting a new resident in Sofia Mattsson. The former General Hospital actress will be jumping networks to NBC’s Days of our Lives, the soap announced in a joint post shared to Instagram. “Sofia Mattsson is making her way to Salem early next year! ⏳…",
        "url": "http://deadline.com/2026/03/sofia-mattsson-days-of-our-lives-cast-addition-1236769635/",
        "date": "2026-03-31",
        "published_at": "2026-03-31T02:48:43Z",
        "sentiment": {
          "label": "positive",
          "score": 0.4,
          "confidence": 0.4
        }
      },
      {
        "source": "news",
        "source_name": "Pypi.org",
        "title": "aimio-py added to PyPI",
        "description": "Python bindings for the Numerics88 AimIO C++ library",
        "url": "https://pypi.org/project/aimio-py/",
        "date": "2026-03-31",
        "published_at": "2026-03-31T02:47:14Z",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "news",
        "source_name": "Pypi.org",
        "title": "ez-stack 0.2.11",
        "description": "Stacked PRs for GitHub — agent-first CLI for parallel development",
        "url": "https://pypi.org/project/ez-stack/",
        "date": "2026-03-31",
        "published_at": "2026-03-31T00:17:47Z",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "news",
        "source_name": "Pypi.org",
        "title": "acp-gh 1.5.0",
        "description": "Automatic Commit Pusher (acp) - CLI tool to create GitHub PRs from staged changes in a single command",
        "url": "https://pypi.org/project/acp-gh/1.5.0/",
        "date": "2026-03-30",
        "published_at": "2026-03-30T23:12:09Z",
        "sentiment": {
          "label": "positive",
          "score": 0.511,
          "confidence": 0.51
        }
      },
      {
        "source": "news",
        "source_name": "Thechronicle.com.gh",
        "title": "Police Gun Down Suspected Armed Robber on Atebubu–Ejura Highway",
        "description": "The Ghana Police Service has allegedly shot dead a suspected notorious armed robber, Osman Amadu, popularly known as “Manu,” during an intelligence-led operation along the Atebubu–Ejura highway. According to police reports, the incident occurred on March 18, …",
        "url": "https://thechronicle.com.gh/police-gun-down-suspected-armed-robber-on-atebubu-ejura-highway/",
        "date": "2026-03-30",
        "published_at": "2026-03-30T17:22:17Z",
        "sentiment": {
          "label": "negative",
          "score": -0.95,
          "confidence": 0.95
        }
      },
      {
        "source": "news",
        "source_name": "Pypi.org",
        "title": "gh-bin 2.89.0",
        "description": "A thin wrapper to distribute https://github.com/cli/cli via pip.",
        "url": "https://pypi.org/project/gh-bin/2.89.0/",
        "date": "2026-03-30",
        "published_at": "2026-03-30T16:16:36Z",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "news",
        "source_name": "Pypi.org",
        "title": "wizardenv added to PyPI",
        "description": "A powerful AI SDK with vision, speech, and multi-backend support",
        "url": "https://pypi.org/project/wizardenv/",
        "date": "2026-03-30",
        "published_at": "2026-03-30T15:03:36Z",
        "sentiment": {
          "label": "positive",
          "score": 0.758,
          "confidence": 0.76
        }
      },
      {
        "source": "news",
        "source_name": "Stephenjude.me",
        "title": "How to Setup PIE for PHP Extensions on macOS",
        "description": "Pie is the official PHP extension installer and the replacement for PECL. In this article, I will show you how to get Pie up and running on your local machine.",
        "url": "https://stephenjude.me/articles/how-to-setup-pie-for-php-extensions-on-macos?utm_source=laravelnews&utm_medium=link&utm_campaign=laravelnews",
        "date": "2026-03-30",
        "published_at": "2026-03-30T13:00:00Z",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "news",
        "source_name": "Thechronicle.com.gh",
        "title": "Donors cheer up SHS Arts students for decorating Asokwa Interchange",
        "description": "Individuals and institutions have trooped to the Asokwa Interchange with food, drinks and cash donations to support Visual Arts students from Senior High Schools who are engaged in decorating the Asokwa Interchange. The project forms part of the novelle Ashan…",
        "url": "https://thechronicle.com.gh/donors-cheer-up-shs-arts-students-for-decorating-asokwa-interchange/",
        "date": "2026-03-30",
        "published_at": "2026-03-30T12:05:55Z",
        "sentiment": {
          "label": "positive",
          "score": 0.827,
          "confidence": 0.83
        }
      },
      {
        "source": "news",
        "source_name": "Thechronicle.com.gh",
        "title": "Filmmakers Summit Held in Kumasi to boost Kumawood Industry",
        "description": "A Filmmakers Summit has been held in Kumasi to revitalise the Ghanaian film industry as part of the Ashanti Festival 2026. Secretary to the Kumawood Board of Directors, Emmanuel Opoku Anane, said the summit is designed to enhance the industry’s vibrancy and s…",
        "url": "https://thechronicle.com.gh/filmmakers-summit-held-in-kumasi-to-boost-kumawood-industry/",
        "date": "2026-03-30",
        "published_at": "2026-03-30T12:01:36Z",
        "sentiment": {
          "label": "positive",
          "score": 0.71,
          "confidence": 0.71
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "Gene Panel Market Size to Projected Reach USD 17.18 Billion by 2035, Driven by Precision Medicine Adoption – SNS Insider",
        "description": "Rising demand for early disease detection, expanding oncology applications, and rapid advancements in next-generation sequencing technologies propel market growth at 16.69% CAGR. Rising demand for early disease detection, expanding oncology applications, and …",
        "url": "https://www.globenewswire.com/news-release/2026/03/30/3264508/0/en/Gene-Panel-Market-Size-to-Projected-Reach-USD-17-18-Billion-by-2035-Driven-by-Precision-Medicine-Adoption-SNS-Insider.html",
        "date": "2026-03-30",
        "published_at": "2026-03-30T11:12:00Z",
        "sentiment": {
          "label": "positive",
          "score": 0.178,
          "confidence": 0.18
        }
      },
      {
        "source": "news",
        "source_name": "Github.com",
        "title": "Show HN: Ag.sh – All-in-one CLI tool to do parallelised AI development with ease",
        "description": "Command-line ADE tooling to run multiple Claude Code/AI agents in parallel - each in its own isolated git worktree.  Spawn, manage, and orchestrate AI-powered development across concurrent tasks wi...",
        "url": "https://github.com/andrewhathaway/ag.sh",
        "date": "2026-03-30",
        "published_at": "2026-03-30T11:01:13Z",
        "sentiment": {
          "label": "positive",
          "score": 0.052,
          "confidence": 0.05
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "Oncology Biomarkers Market Trends and Investment Opportunities Report 2026-2030: Global, Regional and Country-Level Outlook",
        "description": "Rising demand for personalized oncology therapies, AI-driven biomarker discovery, expanding precision diagnostics, and liquid biopsy tech Rising demand for personalized oncology therapies, AI-driven biomarker discovery, expanding precision diagnostics, and li…",
        "url": "https://www.globenewswire.com/news-release/2026/03/30/3264368/28124/en/Oncology-Biomarkers-Market-Trends-and-Investment-Opportunities-Report-2026-2030-Global-Regional-and-Country-Level-Outlook.html",
        "date": "2026-03-30",
        "published_at": "2026-03-30T08:58:00Z",
        "sentiment": {
          "label": "positive",
          "score": 0.153,
          "confidence": 0.15
        }
      },
      {
        "source": "news",
        "source_name": "Pythonbytes.fm",
        "title": "Python Bytes: #475 Haunted warehouses",
        "description": "News and announcements from the Python community for the week of Mar 30th, 2026",
        "url": "https://pythonbytes.fm/episodes/show/475/haunted-warehouses",
        "date": "2026-03-30",
        "published_at": "2026-03-30T08:00:00Z",
        "sentiment": {
          "label": "negative",
          "score": -0.477,
          "confidence": 0.48
        }
      },
      {
        "source": "news",
        "source_name": "Github.com",
        "title": "simonw/claude-code-transcripts: Tools for publishing transcripts for Claude Code sessions",
        "description": "Tools for publishing transcripts for Claude Code sessions - simonw/claude-code-transcripts",
        "url": "https://github.com/simonw/claude-code-transcripts",
        "date": "2026-03-30",
        "published_at": "2026-03-30T05:47:01Z",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "news",
        "source_name": "Pypi.org",
        "title": "gh-worktree 0.3.1",
        "description": "github CLI extension for worktrees",
        "url": "https://pypi.org/project/gh-worktree/0.3.1/",
        "date": "2026-03-29",
        "published_at": "2026-03-29T22:48:33Z",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "news",
        "source_name": "Pypi.org",
        "title": "claude-podman added to PyPI",
        "description": "Run Claude Code CLI in a Podman container with tmux, GitHub access, and persistent config",
        "url": "https://pypi.org/project/claude-podman/",
        "date": "2026-03-29",
        "published_at": "2026-03-29T19:35:55Z",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "news",
        "source_name": "Github.com",
        "title": "Show HN: Baton – A daemon that sends Claude to fix your GitHub issues",
        "description": "I got tired of the context-switching loop: pick an issue, read the context, write the code, open a PR, pick the next one. So I built Baton — a Python daemon that polls your GitHub issue tracker and dispatches Claude Code agents to work on them autonomously.Ho…",
        "url": "https://github.com/mraza007/baton",
        "date": "2026-03-29",
        "published_at": "2026-03-29T16:57:05Z",
        "sentiment": {
          "label": "negative",
          "score": -0.44,
          "confidence": 0.44
        }
      },
      {
        "source": "news",
        "source_name": "Pypi.org",
        "title": "ansel-cli added to PyPI",
        "description": "don't leave crumbs in the woods",
        "url": "https://pypi.org/project/ansel-cli/",
        "date": "2026-03-29",
        "published_at": "2026-03-29T16:47:06Z",
        "sentiment": {
          "label": "neutral",
          "score": 0.038,
          "confidence": 0.04
        }
      },
      {
        "source": "news",
        "source_name": "Github.com",
        "title": "GitHub - axeldelafosse/loop: Dead-simple Bun CLI that runs Codex and Claude Code in a loop. · GitHub",
        "description": "axeldelafosse/loop: Dead-simple Bun CLI that runs Codex and Claude Code in a loop. https://ift.tt/KJUYeRg ai, codex, claude.code, programming",
        "url": "https://github.com/axeldelafosse/loop",
        "date": "2026-03-29",
        "published_at": "2026-03-29T05:47:02Z",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "news",
        "source_name": "Pypi.org",
        "title": "gh-worktree 0.3.0",
        "description": "github CLI extension for worktrees",
        "url": "https://pypi.org/project/gh-worktree/0.3.0/",
        "date": "2026-03-28",
        "published_at": "2026-03-28T23:26:34Z",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "news",
        "source_name": "Pypi.org",
        "title": "fastmvc-cli added to PyPI",
        "description": "FastMVC CLI — interactive FastAPI project generator and tooling",
        "url": "https://pypi.org/project/fastmvc-cli/",
        "date": "2026-03-28",
        "published_at": "2026-03-28T16:33:56Z",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "news",
        "source_name": "Github.com",
        "title": "Show HN: Open Source 'Conductor + Ghostty'",
        "description": "Our team works with Claude Code, Codex, Gemini all day.\nWe love Ghostty, but wanted something where we could work in multiple worktree at once and have multiple agents run.We decided to open source the internal team we use. Hope you might find it useful. Free…",
        "url": "https://github.com/stablyai/orca",
        "date": "2026-03-27",
        "published_at": "2026-03-27T22:26:40Z",
        "sentiment": {
          "label": "positive",
          "score": 0.883,
          "confidence": 0.88
        }
      },
      {
        "source": "news",
        "source_name": "Pypi.org",
        "title": "acp-gh 1.4.0",
        "description": "Automatic Commit Pusher (acp) - CLI tool to create GitHub PRs from staged changes in a single command",
        "url": "https://pypi.org/project/acp-gh/1.4.0/",
        "date": "2026-03-27",
        "published_at": "2026-03-27T21:39:52Z",
        "sentiment": {
          "label": "positive",
          "score": 0.511,
          "confidence": 0.51
        }
      },
      {
        "source": "news",
        "source_name": "Github.com",
        "title": "Velxio 2.0 – Emulate Arduino, ESP32, and Raspberry Pi 3 in the Browser",
        "description": "Emulate Arduino, ESP32 &amp; Raspberry Pi. in your browser. Write code, compile, and run on 19 real boards — Arduino Uno, ESP32, ESP32-C3, Raspberry Pi Pico, Raspberry Pi 3, and more. No hardware, ...",
        "url": "https://github.com/davidmonterocrespo24/velxio",
        "date": "2026-03-27",
        "published_at": "2026-03-27T20:44:33Z",
        "sentiment": {
          "label": "negative",
          "score": -0.36,
          "confidence": 0.36
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "Colorectal Cancer Advocates Urge Congress to Fund New Research",
        "description": "With Young Lives at Stake, More Than 250 Colorectal Cancer Advocates Demand Action With Young Lives at Stake, More Than 250 Colorectal Cancer Advocates Demand Action",
        "url": "https://www.globenewswire.com/news-release/2026/03/27/3263970/0/en/Colorectal-Cancer-Advocates-Urge-Congress-to-Fund-New-Research.html",
        "date": "2026-03-27",
        "published_at": "2026-03-27T16:31:00Z",
        "sentiment": {
          "label": "negative",
          "score": -0.945,
          "confidence": 0.95
        }
      },
      {
        "source": "news",
        "source_name": "Plos.org",
        "title": "Glucocorticoid-Induced alterations in DNA methylation in the H19 promoter of Bone Marrow-Derived Mesenchymal Stem Cells are associated with the pathogenesis of osteonecrosis",
        "description": "Background Glucocorticoid (GC)-induced osteonecrosis of the femoral head (ONFH) involves bone marrow-derived mesenchymal stem cell (BMSC) apoptosis and dysregulated osteo-adipogenic differentiation. While aberrant H19 promoter methylation and expression have …",
        "url": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0345372",
        "date": "2026-03-27",
        "published_at": "2026-03-27T14:00:00Z",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "Zinc Chemicals Market to Reach USD 16.17 Billion by 2035, Fueled by Rising Demand in Rubber, Agriculture, and Industrial Applications | Research by SNS Insider",
        "description": "The Zinc Chemicals Market is growing steadily as demand rises for zinc-based fertilizers, rubber additives, and industrial formulations, with the U.S. segment increasing from USD 1.86 billion in 2025 to USD 2.82 billion by 2035. The Zinc Chemicals Market is g…",
        "url": "https://www.globenewswire.com/news-release/2026/03/27/3263802/0/en/Zinc-Chemicals-Market-to-Reach-USD-16-17-Billion-by-2035-Fueled-by-Rising-Demand-in-Rubber-Agriculture-and-Industrial-Applications-Research-by-SNS-Insider.html",
        "date": "2026-03-27",
        "published_at": "2026-03-27T13:30:00Z",
        "sentiment": {
          "label": "negative",
          "score": -0.052,
          "confidence": 0.05
        }
      },
      {
        "source": "news",
        "source_name": "Pypi.org",
        "title": "caalm added to PyPI",
        "description": "Carbohydrate Activity Annotation with protein Language Models",
        "url": "https://pypi.org/project/caalm/",
        "date": "2026-03-27",
        "published_at": "2026-03-27T08:29:51Z",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "news",
        "source_name": "Thechronicle.com.gh",
        "title": "Two Jailed for Stealing Motorbike Worth GH¢10,500",
        "description": "The Circuit Court at Dansoman has sentenced two young men to prison for stealing a motorbike valued at GH¢10,500. The convicts, Abdul Aziz Osman, 20, unemployed and Abdul Aziz Mohammed, 22, also unemployed, were sentenced by the court presided over by Her Hon…",
        "url": "https://thechronicle.com.gh/two-jailed-for-stealing-motorbike-worth-gh¢10500/",
        "date": "2026-03-27",
        "published_at": "2026-03-27T08:00:45Z",
        "sentiment": {
          "label": "negative",
          "score": -0.883,
          "confidence": 0.88
        }
      },
      {
        "source": "news",
        "source_name": "Thechronicle.com.gh",
        "title": "Fashion Designer remanded over alleged possession, use of counterfeit money",
        "description": "The Circuit Court in Tarkwa, presided over by Her Honour Bernice Mensimah Ackon, has remanded a 40-year-old fashion designer, Grace Arthur, into custody for allegedly possessing and uttering counterfeit Ghana cedi notes at Wasa Akropong in the Western Region.…",
        "url": "https://thechronicle.com.gh/fashion-designer-remanded-over-alleged-possession-use-of-counterfeit-money/",
        "date": "2026-03-27",
        "published_at": "2026-03-27T07:58:51Z",
        "sentiment": {
          "label": "positive",
          "score": 0.758,
          "confidence": 0.76
        }
      },
      {
        "source": "news",
        "source_name": "Thechronicle.com.gh",
        "title": "Businessman Jailed 24 Months for GH¢180,000 Visa Fraud",
        "description": "The Dansoman Circuit Court has sentenced a 29-year-old businessman, Charles Komla Asigbey, to 24 months imprisonment for defrauding seven persons of GH¢180,000 under the pretext of securing visas for them to travel abroad. The court, presided over by Her Hono…",
        "url": "https://thechronicle.com.gh/businessman-jailed-24-months-for-gh¢180000-visa-fraud/",
        "date": "2026-03-27",
        "published_at": "2026-03-27T07:56:52Z",
        "sentiment": {
          "label": "negative",
          "score": -0.9,
          "confidence": 0.9
        }
      },
      {
        "source": "news",
        "source_name": "Thechronicle.com.gh",
        "title": "ECG delivers an impressive operational performance in 2025",
        "description": "The Eastern Regional office of the Electricity Company of Ghana (ECG) has delivered an impressive operational performance in 2025, underpinned by improved power stability, strategic infrastructure investments, and a renewed crackdown on illegal electricity us…",
        "url": "https://thechronicle.com.gh/ecg-delivers-an-impressive-operational-performance-in-2025/",
        "date": "2026-03-27",
        "published_at": "2026-03-27T07:46:12Z",
        "sentiment": {
          "label": "positive",
          "score": 0.727,
          "confidence": 0.73
        }
      },
      {
        "source": "news",
        "source_name": "ComingSoon.net",
        "title": "GH’s Marco Star Adrian Anchondo Gets Tribute From Boyfriend After Exit",
        "description": "Fans have bid farewell to General Hospital‘s Marco, portrayed by Adrian Anchondo, and his boyfriend has now shared his reaction to his exit. Fellow soap opera star Colton Little shared an emotional tribute after Anchondo’s surprise departure from GH. Adrian A…",
        "url": "https://www.comingsoon.net/tv/news/2112893-general-hospital-gh-adrian-anchondo-leave-exit-marco-death-reaction",
        "date": "2026-03-27",
        "published_at": "2026-03-27T05:24:50Z",
        "sentiment": {
          "label": "positive",
          "score": 0.713,
          "confidence": 0.71
        }
      },
      {
        "source": "news",
        "source_name": "Thechronicle.com.gh",
        "title": "Haruna Iddrisu throws $27,000 lifeline for fourth surgery of six-year-old boy",
        "description": "The Member of Parliament for Tamale North, Haruna Iddrisu, has funded a fourth life-saving surgery for a six-year-old boy, Abdula Hannan at the KomfoAnokye Teaching Hospital.The little boy has a prolonged medical condition caused by accidental ingestion of a …",
        "url": "https://thechronicle.com.gh/haruna-iddrisu-throws-27000-lifeline-for-fourth-surgery-of-six-year-old-boy/",
        "date": "2026-03-27",
        "published_at": "2026-03-27T00:41:00Z",
        "sentiment": {
          "label": "negative",
          "score": -0.077,
          "confidence": 0.08
        }
      },
      {
        "source": "news",
        "source_name": "Nature.com",
        "title": "Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial",
        "description": "In the nonpivotal stage 1 of the randomized phase 3 PRESERVE-003 trial, patients with immunochemotherapy-resistant metastatic squamous non-small cell lung cancer without actionable genomic alterations treated with the next-generation, pH-sensitive anti-CTLA-4…",
        "url": "https://www.nature.com/articles/s41591-026-04323-8",
        "date": "2026-03-27",
        "published_at": "2026-03-27T00:00:00Z",
        "sentiment": {
          "label": "negative",
          "score": -0.869,
          "confidence": 0.87
        }
      },
      {
        "source": "news",
        "source_name": "Royal Society of Chemistry",
        "title": "Atmosphere-dependent synthesis and crystallization behavior of silica nanoparticles derived from rice husk biomass",
        "description": "RSC Adv., 2026, 16,16874-16886DOI: 10.1039/D6RA00367B, Paper Open Access &nbsp This article is licensed under a Creative Commons Attribution 3.0 Unported Licence.Fuad Hama Shareef Radha, Mohammad Tahir Kareem, Omed Gh. AbdullahThis work on sustainable nanomat…",
        "url": "https://pubs.rsc.org/en/content/articlelanding/2026/ra/d6ra00367b",
        "date": "2026-03-27",
        "published_at": "2026-03-27T00:00:00Z",
        "sentiment": {
          "label": "positive",
          "score": 0.44,
          "confidence": 0.44
        }
      },
      {
        "source": "news",
        "source_name": "Pypi.org",
        "title": "ticktick-agent-cli added to PyPI",
        "description": "Agent-native CLI for TickTick task management — full API coverage via V1 + V2",
        "url": "https://pypi.org/project/ticktick-agent-cli/",
        "date": "2026-03-26",
        "published_at": "2026-03-26T23:19:31Z",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "IMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 Results",
        "description": "NASHVILLE, Tenn., March 26, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with its fourth quarter results:",
        "url": "https://www.globenewswire.com/news-release/2026/03/26/3263407/0/en/IMDX-Submits-GraftAssureDx-for-FDA-Review-and-Reports-Q4-2025-Results.html",
        "date": "2026-03-26",
        "published_at": "2026-03-26T20:05:00Z",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "news",
        "source_name": "Pypi.org",
        "title": "gh-license 0.4.0",
        "description": "Scan github, bitbucket or other providers repositories for missing license files and add them",
        "url": "https://pypi.org/project/gh-license/0.4.0/",
        "date": "2026-03-26",
        "published_at": "2026-03-26T18:26:05Z",
        "sentiment": {
          "label": "negative",
          "score": -0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "news",
        "source_name": "Pypi.org",
        "title": "rcpilot added to PyPI",
        "description": "Lightweight self-hosted session manager for Claude Code Remote Control",
        "url": "https://pypi.org/project/rcpilot/",
        "date": "2026-03-26",
        "published_at": "2026-03-26T17:43:19Z",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "news",
        "source_name": "Ssrf.dev",
        "title": "個人的にGitHub Actionsまわりで気をつけていること | ssrf.dev",
        "description": "目次ghalint / actionlintに頼る3rd party actionをできるだけ使わないSecretsにKeyを置かないやろうと思っているけど徹底できていないことRequire actions to be pinned to a full-length commit SHAの有効化branch ruleset / push rulesetghalint / actionlintを全リポジトリで回すさいごに 2026年も引き続きGitHub Ac...",
        "url": "https://ssrf.dev/posts/2026/03/27/personal-gha-security-tips/",
        "date": "2026-03-26",
        "published_at": "2026-03-26T16:50:38Z",
        "sentiment": {
          "label": "positive",
          "score": 0.599,
          "confidence": 0.6
        }
      },
      {
        "source": "news",
        "source_name": "Plos.org",
        "title": "Repurposing mebendazole to reprogram oncogenic and tumor-suppressor networks: Multi-cancer insights from ENOX2, MMP2, RASSF1A, WFDC10A and METTL7A",
        "description": "Background Cancer progression involves coordinated regulation of oncogenes and tumor suppressors. This study explores the interplay of ENOX2 (ecto-NADH oxidase disulfide-thiol exchanger 2), MMP2 (matrix metalloproteinase-2), and regulatory genes Ras Associati…",
        "url": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0345701",
        "date": "2026-03-26",
        "published_at": "2026-03-26T14:00:00Z",
        "sentiment": {
          "label": "negative",
          "score": -0.791,
          "confidence": 0.79
        }
      },
      {
        "source": "news",
        "source_name": "Plos.org",
        "title": "Holding it all together: Family caregivers’ support needs after very early supported discharge post stroke",
        "description": "Background Early supported discharge (ESD) facilitates the transition from specialized stroke units to home-based rehabilitation in familiar environments. While ESD has shown positive outcomes for people with stroke, little is known about how their family car…",
        "url": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0345795",
        "date": "2026-03-26",
        "published_at": "2026-03-26T14:00:00Z",
        "sentiment": {
          "label": "positive",
          "score": 0.88,
          "confidence": 0.88
        }
      },
      {
        "source": "news",
        "source_name": "Plos.org",
        "title": "Cell cycle dynamics regulate H3K27 and H3K9 histone modifications in Drosophila",
        "description": "Previous studies have established a link between cell cycle progression and histone modification dynamics, but how this is regulated in vivo has remained largely explored. This study shows that the levels of H3K27ac, H3K27me3, and H3K9me3 are tightly linked t…",
        "url": "https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.3003371",
        "date": "2026-03-26",
        "published_at": "2026-03-26T14:00:00Z",
        "sentiment": {
          "label": "positive",
          "score": 0.273,
          "confidence": 0.27
        }
      },
      {
        "source": "news",
        "source_name": "Pypi.org",
        "title": "ghboot added to PyPI",
        "description": "Bootstrap an empty directory into a git repo with a GitHub remote",
        "url": "https://pypi.org/project/ghboot/",
        "date": "2026-03-26",
        "published_at": "2026-03-26T12:06:22Z",
        "sentiment": {
          "label": "negative",
          "score": -0.202,
          "confidence": 0.2
        }
      },
      {
        "source": "news",
        "source_name": "Barbero.tech",
        "title": "Mikael Barbero: Don't become the next Trivy: how to make your releases, tags, and automation resistant to compromise",
        "description": "This is Part 2 of our response to the Trivy supply-chain compromise. Part 1 covered how to consume GitHub Actions safely. This post covers the other side: how to publish safely, so your project doesn’t become the upstream incident that impacts everyone downst…",
        "url": "https://mikael.barbero.tech/blog/post/2026-03-26-dont-become-the-next-trivy/",
        "date": "2026-03-26",
        "published_at": "2026-03-26T08:30:00Z",
        "sentiment": {
          "label": "positive",
          "score": 0.751,
          "confidence": 0.75
        }
      },
      {
        "source": "news",
        "source_name": "Thechronicle.com.gh",
        "title": "MIIF Records GH¢5.3bn in Mineral Royalties in 2025 – Up from GH¢4.91bn in 2024",
        "description": "When the Chief Executive Officer (CEO) of the Minerals Income Investment Fund (MIIF), Justina Nelson, addressed editors and senior journalists in Accra, yesterday, she set the tone with a defining statistic, MIIF recorded GH¢5.3 billion in mineral royalties i…",
        "url": "https://thechronicle.com.gh/miif-records-gh¢5-3bn-in-mineral-royalties-in-2025-up-from-gh¢4-91bn-in-2024/",
        "date": "2026-03-26",
        "published_at": "2026-03-26T08:15:50Z",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "news",
        "source_name": "Thechronicle.com.gh",
        "title": "Rising Kidney Disease Burden Triggers Fresh Push for Food Labelling Reform",
        "description": "A growing body of scientific and public health evidence is raising alarms over the rapid rise of Chronic Kidney Disease (CKD) in Ghana. Policy advocates are now calling for urgent reforms to the country’s food labelling system to curb what they describe as a …",
        "url": "https://thechronicle.com.gh/rising-kidney-disease-burden-triggers-fresh-push-for-food-labelling-reform/",
        "date": "2026-03-26",
        "published_at": "2026-03-26T08:06:08Z",
        "sentiment": {
          "label": "negative",
          "score": -0.052,
          "confidence": 0.05
        }
      },
      {
        "source": "news",
        "source_name": "Thechronicle.com.gh",
        "title": "Editorial: Ghana Is Paying Billions To Treat A Disease It Could Have Prevented",
        "description": "Four million Ghanaians, according to available statistics, are living with chronic kidney disease, but regrettably, most of them do not know it. The condition advances without symptoms, recruiting patients silently until it reaches the stage where the only av…",
        "url": "https://thechronicle.com.gh/editorial-ghana-is-paying-billions-to-treat-a-disease-it-could-have-prevented/",
        "date": "2026-03-26",
        "published_at": "2026-03-26T07:58:11Z",
        "sentiment": {
          "label": "negative",
          "score": -0.421,
          "confidence": 0.42
        }
      },
      {
        "source": "news",
        "source_name": "Biblegateway.com",
        "title": "Chronological Reading for Thursday March 26, 2026 (NIV)",
        "description": "",
        "url": "https://www.biblegateway.com/reading-plans/chronological/2026/03/26/",
        "date": "2026-03-26",
        "published_at": "2026-03-26T04:05:04Z",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "news",
        "source_name": "Eclipsesource.com",
        "title": "The Eclipse Theia Community Release 2026-02",
        "description": "We are happy to announce the thirteenth Eclipse Theia community release, “2026-02,” incorporating the latest advances from Theia releases 1.67 and 1.68.\nNew to Eclipse Theia? It is the next-generation …The post The Eclipse Theia Community Release 2026-02\nappe…",
        "url": "https://eclipsesource.com/blogs/2026/03/26/the-eclipse-theia-community-release-2026-02/",
        "date": "2026-03-26",
        "published_at": "2026-03-26T00:00:00Z",
        "sentiment": {
          "label": "positive",
          "score": 0.572,
          "confidence": 0.57
        }
      },
      {
        "source": "news",
        "source_name": "Github.com",
        "title": "Show HN: Sift – local, de-noised GitHub notifications",
        "description": "Sift is an open source local GitHub inbox organizer.GitHub notifications are good at collecting activity and weak at prioritizing it. Sift pulls your inbox and adjacent repo activity into a local SQLite database, classifies it with explicit rules, and gives y…",
        "url": "https://github.com/vignesh07/sift",
        "date": "2026-03-25",
        "published_at": "2026-03-25T17:39:07Z",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRD",
        "description": "DUBLIN, March 25, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced two peer-reviewed …",
        "url": "https://www.globenewswire.com/news-release/2026/03/25/3262385/0/en/GH-Research-Announces-Publication-of-Phase-2b-Results-for-Mebufotenin-GH001-in-JAMA-Psychiatry-and-Reports-New-Finding-of-Severity-Independent-Efficacy-in-TRD.html",
        "date": "2026-03-25",
        "published_at": "2026-03-25T15:10:00Z",
        "sentiment": {
          "label": "negative",
          "score": -0.178,
          "confidence": 0.18
        }
      },
      {
        "source": "news",
        "source_name": "Plos.org",
        "title": "Assessment of long COVID symptom burden in patients testing positive for SARS-CoV-2 at a nationwide retail pharmacy",
        "description": "Background Numerous grouping and scoring methodologies have been proposed to assess long COVID symptomatology. One approach is to use symptom count as a simple, quantifiable measure of long COVID symptom burden.   Methods This was a secondary analysis of a na…",
        "url": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0345639",
        "date": "2026-03-25",
        "published_at": "2026-03-25T14:00:00Z",
        "sentiment": {
          "label": "negative",
          "score": -0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "news",
        "source_name": "Plos.org",
        "title": "M5 positive allosteric modulation alleviates parkinsonian motor deficits",
        "description": "Parkinson’s disease is a neurodegenerative movement disorder which is characterized by cardinal motor symptoms of tremor at rest, rigidity, bradykineasia, and postural instability. Underlying these cardinal motor symptoms is thought to be death and dysfunctio…",
        "url": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0345115",
        "date": "2026-03-25",
        "published_at": "2026-03-25T14:00:00Z",
        "sentiment": {
          "label": "negative",
          "score": -0.572,
          "confidence": 0.57
        }
      },
      {
        "source": "news",
        "source_name": "Pypi.org",
        "title": "graniteclaw added to PyPI",
        "description": "Agent specification certification pipeline — from skill specs to governed, certified Mellea pipelines",
        "url": "https://pypi.org/project/graniteclaw/",
        "date": "2026-03-25",
        "published_at": "2026-03-25T12:43:20Z",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "news",
        "source_name": "Github.com",
        "title": "Show HN: Clinic – Connect your agent to Gmail, GitHub, Notion and 39 more (OSS)",
        "description": "Your AI agent can't access your Gmail, your GitHub, or your Notion. Most of these services already have CLIs built for programmatic access, but nobody's set them up, authenticated them, and told the agent they're there.Clinic does it in one command: clinic in…",
        "url": "https://github.com/jwvictor/clinic",
        "date": "2026-03-25",
        "published_at": "2026-03-25T12:42:39Z",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "news",
        "source_name": "Thechronicle.com.gh",
        "title": "OSP withdraws charges against two accused in NPA Trial",
        "description": "The Office of the Special Prosecutor (OSP) has withdrawn charges against two persons who were standing trial together with former Chief Executive of the National Petroleum Authority (NPA), Dr Mustapha Abdul-Hamid, and others in an alleged extortion case. The …",
        "url": "https://thechronicle.com.gh/osp-withdraws-charges-against-two-accused-in-npa-trial/",
        "date": "2026-03-25",
        "published_at": "2026-03-25T09:29:03Z",
        "sentiment": {
          "label": "negative",
          "score": -0.34,
          "confidence": 0.34
        }
      },
      {
        "source": "news",
        "source_name": "Yahoo Entertainment",
        "title": "What Does GH Research PLC (GHRS)’s Clinical Progress Updates Say?",
        "description": "",
        "url": "https://consent.yahoo.com/v2/collectConsent?sessionId=1_cc-session_4821a93d-833b-4229-a256-4e7bc617a16b",
        "date": "2026-03-25",
        "published_at": "2026-03-25T05:34:14Z",
        "sentiment": {
          "label": "positive",
          "score": 0.421,
          "confidence": 0.42
        }
      },
      {
        "source": "news",
        "source_name": "Hacker News",
        "title": "Show HN: GitHub Actions for Agents",
        "description": "Hi everyone,I really dislike the fix, commit, and wait loop that is involved with CI. I decided to fix that by shortening the loop. I did that by mocking the GH Actions control pane: the runner is the official GH runner, but the API is a mock.What you get is …",
        "url": "https://news.ycombinator.com/item?id=47513068",
        "date": "2026-03-25",
        "published_at": "2026-03-25T03:56:51Z",
        "sentiment": {
          "label": "negative",
          "score": -0.295,
          "confidence": 0.3
        }
      },
      {
        "source": "news",
        "source_name": "Frontendfoc.us",
        "title": "The Great CSS Expansion: Replacing JS with native features",
        "description": "<table>\n <tr><td>\n \n<table><tr><td></td></tr></table>\n\n<table><tr><td></td></tr></table>\n<table><tr><td>\n\n<table><tr><td>\n <table>\n <tr>\n <td>\n <table><tr><td> Frontend Focus</td></tr></table>\n\n #​734 — March 25, 2026 | Read on the web\r\n\n </td>\n </tr>\n </ta…",
        "url": "https://frontendfoc.us/issues/734",
        "date": "2026-03-25",
        "published_at": "2026-03-25T00:00:00Z",
        "sentiment": {
          "label": "positive",
          "score": 0.625,
          "confidence": 0.62
        }
      },
      {
        "source": "news",
        "source_name": "Pypi.org",
        "title": "p6xer-mcp-server added to PyPI",
        "description": "MCP server for Primavera P6 XER schedule files — parse, analyze, and quality-check with AI",
        "url": "https://pypi.org/project/p6xer-mcp-server/",
        "date": "2026-03-24",
        "published_at": "2026-03-24T18:10:39Z",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "news",
        "source_name": "Pypi.org",
        "title": "git-sift added to PyPI",
        "description": "Interactive wizard for reviewing AI-generated code changes by risk",
        "url": "https://pypi.org/project/git-sift/",
        "date": "2026-03-24",
        "published_at": "2026-03-24T16:14:52Z",
        "sentiment": {
          "label": "negative",
          "score": -0.273,
          "confidence": 0.27
        }
      },
      {
        "source": "news",
        "source_name": "Plos.org",
        "title": "Subject-specific modeling of response to physical stress via hypothalamic-pituitary-adrenal and sympathoadrenal axes",
        "description": "The two main pathways for hormonal stress response are the hypothalamic-pituitary- adrenal (HPA) axis and the sympathoadrenal (SA) axis. The HPA axis produces and secretes cortisol, while the SA axis produces and secretes the fast-acting catecholamines, epine…",
        "url": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0344981",
        "date": "2026-03-24",
        "published_at": "2026-03-24T14:00:00Z",
        "sentiment": {
          "label": "negative",
          "score": -0.681,
          "confidence": 0.68
        }
      },
      {
        "source": "news",
        "source_name": "Plos.org",
        "title": "Risk assessment for cardiovascular adverse drug events in the ICU: Case study on COVID-19 patients",
        "description": "The COVID-19 outbreak quickly became a pandemic. In Brazil, more than seven million cases were recorded in 2020. Most patients affected by the disease were admitted to intensive care units (ICU), requiring qualitative polypharmacy, increasing the risk of seri…",
        "url": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0345280",
        "date": "2026-03-24",
        "published_at": "2026-03-24T14:00:00Z",
        "sentiment": {
          "label": "negative",
          "score": -0.455,
          "confidence": 0.45
        }
      },
      {
        "source": "news",
        "source_name": "Barbero.tech",
        "title": "Mikael Barbero: Stop trusting mutable references: how Eclipse Foundation projects should harden GitHub Actions after the Trivy compromise",
        "description": "On March 19, 2026, an attacker used compromised credentials to publish a malicious Trivy v0.69.4 release, force-push 76 of 77 version tags in aquasecurity/trivy-action, and replace all 7 tags in aquasecurity/setup-trivy with malicious commits. On March 22, Aq…",
        "url": "https://mikael.barbero.tech/blog/post/2026-03-24-stop-trusting-mutable-references/",
        "date": "2026-03-24",
        "published_at": "2026-03-24T08:30:00Z",
        "sentiment": {
          "label": "negative",
          "score": -0.477,
          "confidence": 0.48
        }
      },
      {
        "source": "news",
        "source_name": "Github.com",
        "title": "Show HN: ProofShot – Give AI coding agents eyes to verify the UI they build",
        "description": "Contribute to AmElmo/proofshot development by creating an account on GitHub.",
        "url": "https://github.com/AmElmo/proofshot",
        "date": "2026-03-24",
        "published_at": "2026-03-24T07:46:46Z",
        "sentiment": {
          "label": "positive",
          "score": 0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "news",
        "source_name": "Thechronicle.com.gh",
        "title": "Consolidated Bank Staff Steals GH¢1m And US$139k From Bank – Court Told",
        "description": "A 48-year-old Collateral Administrator at Consolidated Bank Ghana, Bonny Freddie Owusu Ansah, has been remanded into police custody by the Dansoman Circuit Court for allegedly stealing more than GH¢1 million and US$139,000 belonging to customers of the bank. …",
        "url": "https://thechronicle.com.gh/consolidated-bank-staff-steals-gh¢1m-and-us139k-from-bank-court-told/",
        "date": "2026-03-24",
        "published_at": "2026-03-24T07:28:10Z",
        "sentiment": {
          "label": "negative",
          "score": -0.791,
          "confidence": 0.79
        }
      },
      {
        "source": "news",
        "source_name": "Thechronicle.com.gh",
        "title": "Dispatch Rider Pleads Guilty To Robbing  Namibian High Commissioner’s Secretary",
        "description": "The Circuit Court at Dansoman, presided over by Her Honour Nancy Teiko Searyoh, has fixed April 1, 2026, to sentence a 24-year-old dispatch rider who pleaded guilty to robbery and causing unlawful damage. The accused, Daniel Asiuebi, pleaded guilty simplicite…",
        "url": "https://thechronicle.com.gh/dispatch-rider-pleads-guilty-to-robbing-namibian-high-commissioners-secretary/",
        "date": "2026-03-24",
        "published_at": "2026-03-24T07:23:45Z",
        "sentiment": {
          "label": "negative",
          "score": -0.832,
          "confidence": 0.83
        }
      },
      {
        "source": "news",
        "source_name": "Thechronicle.com.gh",
        "title": "Farmer services centre for Afram Plains",
        "description": "President John Dramani Mahama has announced plans for the construction of a long-awaited bridge over the Afram River, alongside major agricultural interventions, in what he describes as a decisive step toward transforming the Afram Plains. The announcement wa…",
        "url": "https://thechronicle.com.gh/farmer-services-centre-for-afram-plains/",
        "date": "2026-03-24",
        "published_at": "2026-03-24T07:20:34Z",
        "sentiment": {
          "label": "positive",
          "score": 0.226,
          "confidence": 0.23
        }
      },
      {
        "source": "news",
        "source_name": "Thechronicle.com.gh",
        "title": "Know The Abolished Taxes in Ghana",
        "description": "Ghana’s Parliament has abolished several tax laws since 2024, a decision taken to enhance the tax system, lessen tax burdens on taxpayers, and promote economic growth. This move is part of the government’s RESET Agenda, aimed at reducing the tax burden on cit…",
        "url": "https://thechronicle.com.gh/know-the-abolished-taxes-in-ghana/",
        "date": "2026-03-24",
        "published_at": "2026-03-24T07:06:47Z",
        "sentiment": {
          "label": "negative",
          "score": -0.052,
          "confidence": 0.05
        }
      },
      {
        "source": "pubmed",
        "pmid": "41922144",
        "title": "Gene testing and prognosis in post-operative recurrent non-small-cell lung cancer: subgroup analyses of WJOG15421L.",
        "authors": "Matsubara T et al.",
        "journal": "ESMO open",
        "date": "2026 Mar 3",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41922144/",
        "sentiment": {
          "label": "negative",
          "score": -0.66,
          "confidence": 0.66
        }
      },
      {
        "source": "pubmed",
        "pmid": "41922143",
        "title": "Comparative efficacy of zanubrutinib plus obinutuzumab versus last prior treatment in relapsed/refractory follicular lymphoma: growth modulation index analysis from the ROSEWOOD study.",
        "authors": "Trotman J et al.",
        "journal": "ESMO open",
        "date": "2026 Mar 3",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41922143/",
        "sentiment": {
          "label": "positive",
          "score": 0.382,
          "confidence": 0.38
        }
      },
      {
        "source": "pubmed",
        "pmid": "41917211",
        "title": "Phase 1 study of ceralasertib, an ATR kinase inhibitor, in combination with durvalumab in patients with recurrent or metastatic NSCLC or HNSCC.",
        "authors": "Lopez JS et al.",
        "journal": "British journal of cancer",
        "date": "2026 Mar 3",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41917211/",
        "sentiment": {
          "label": "negative",
          "score": -0.077,
          "confidence": 0.08
        }
      },
      {
        "source": "pubmed",
        "pmid": "41917040",
        "title": "Loss of luminal lineage drives resistance to next-generation ERα antagonists in pretreated ER(+) HER2(-) locally-advanced or metastatic breast cancer.",
        "authors": "Liang J et al.",
        "journal": "Nature communications",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41917040/",
        "sentiment": {
          "label": "negative",
          "score": -1.0,
          "confidence": 1.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41903996",
        "title": "Utility of Circulating Tumor DNA-Based Liquid Biopsies in Patients with Cancer Receiving Immunotherapy.",
        "authors": "Teixeira MF et al.",
        "journal": "Surgical oncology clinics of North America",
        "date": "2026-04-02",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41903996/",
        "sentiment": {
          "label": "negative",
          "score": -0.791,
          "confidence": 0.79
        }
      },
      {
        "source": "pubmed",
        "pmid": "41903301",
        "title": "Phase Ia/Ib trial of the safety and efficacy of mobocertinib in combination with T-DM1 for patients with HER2-mutant solid tumors (WJOG16022M).",
        "authors": "Kanemura H et al.",
        "journal": "European journal of cancer (Oxford, England : 1990)",
        "date": "2026 Mar 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41903301/",
        "sentiment": {
          "label": "positive",
          "score": 0.527,
          "confidence": 0.53
        }
      },
      {
        "source": "pubmed",
        "pmid": "41899521",
        "title": "Association Between Patient-Reported Outcomes and Overall Survival in Patients with Advanced NSCLC Treated with First-Line Cemiplimab-Based Therapy.",
        "authors": "Gandara DR et al.",
        "journal": "Cancers",
        "date": "2026 Mar 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41899521/",
        "sentiment": {
          "label": "positive",
          "score": 0.25,
          "confidence": 0.25
        }
      },
      {
        "source": "pubmed",
        "pmid": "41898529",
        "title": "Genome-Wide CRISPR Screens Identify ABCG2-Mediated Drug Resistance to the Threonine Tyrosine Kinase (TTK) Inhibitor CFI-402257 in Breast Cancer.",
        "authors": "Thu KL et al.",
        "journal": "International journal of molecular sciences",
        "date": "2026 Mar 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41898529/",
        "sentiment": {
          "label": "negative",
          "score": -0.691,
          "confidence": 0.69
        }
      },
      {
        "source": "pubmed",
        "pmid": "41896648",
        "title": "Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial.",
        "authors": "Cho BC et al.",
        "journal": "Nature medicine",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41896648/",
        "sentiment": {
          "label": "negative",
          "score": -0.66,
          "confidence": 0.66
        }
      },
      {
        "source": "pubmed",
        "pmid": "41895789",
        "title": "Comparison of tissue acquisition techniques for Next-Generation Sequencing of non-small cell lung cancer (NSCLC).",
        "authors": "Bhamani A et al.",
        "journal": "BMJ open respiratory research",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41895789/",
        "sentiment": {
          "label": "negative",
          "score": -0.46,
          "confidence": 0.46
        }
      },
      {
        "source": "pubmed",
        "pmid": "41895314",
        "title": "Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaboration.",
        "authors": "Dingemans AC et al.",
        "journal": "The Lancet. Respiratory medicine",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41895314/",
        "sentiment": {
          "label": "negative",
          "score": -0.869,
          "confidence": 0.87
        }
      },
      {
        "source": "pubmed",
        "pmid": "41892875",
        "title": "Baseline tumor burden and outcomes in patients with rare cancers treated with immunotherapy (Southwest Oncology Group trial S1609).",
        "authors": "Swiecicki PL et al.",
        "journal": "Cancer",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41892875/",
        "sentiment": {
          "label": "negative",
          "score": -0.67,
          "confidence": 0.67
        }
      },
      {
        "source": "pubmed",
        "pmid": "41883872",
        "title": "Molecular complete response to the RIN protocol (regorafenib, ipilimumab, and nivolumab) in a patient with advanced recurrent metastatic mismatch repair proficient/microsatellite stable (pMMR/MSS) rectal cancer.",
        "authors": "Qadri F et al.",
        "journal": "Therapeutic advances in medical oncology",
        "date": "2026-04-02",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41883872/",
        "sentiment": {
          "label": "negative",
          "score": -0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "pubmed",
        "pmid": "41882405",
        "title": "Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial.",
        "authors": "Park W et al.",
        "journal": "Nature medicine",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41882405/",
        "sentiment": {
          "label": "negative",
          "score": -0.66,
          "confidence": 0.66
        }
      },
      {
        "source": "pubmed",
        "pmid": "41880871",
        "title": "Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST).",
        "authors": "Kito Y et al.",
        "journal": "European journal of cancer (Oxford, England : 1990)",
        "date": "2026 Mar 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41880871/",
        "sentiment": {
          "label": "negative",
          "score": -0.66,
          "confidence": 0.66
        }
      },
      {
        "source": "pubmed",
        "pmid": "41876649",
        "title": "AI-based chest X-ray prioritization in the lung cancer diagnostic pathway: the LungIMPACT randomized controlled trial.",
        "authors": "Woznitza N et al.",
        "journal": "Nature medicine",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41876649/",
        "sentiment": {
          "label": "negative",
          "score": -0.66,
          "confidence": 0.66
        }
      },
      {
        "source": "pubmed",
        "pmid": "41874648",
        "title": "Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV).",
        "authors": "Mollica V et al.",
        "journal": "Cancer immunology, immunotherapy : CII",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41874648/",
        "sentiment": {
          "label": "positive",
          "score": 0.25,
          "confidence": 0.25
        }
      },
      {
        "source": "pubmed",
        "pmid": "41872602",
        "title": "Implementation of the NHS England Lung Cancer Screening Programme over 5 years.",
        "authors": "Lee RW et al.",
        "journal": "Nature medicine",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41872602/",
        "sentiment": {
          "label": "negative",
          "score": -0.66,
          "confidence": 0.66
        }
      },
      {
        "source": "pubmed",
        "pmid": "41871874",
        "title": "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0.",
        "authors": "McKay RR et al.",
        "journal": "Journal for immunotherapy of cancer",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41871874/",
        "sentiment": {
          "label": "negative",
          "score": -0.66,
          "confidence": 0.66
        }
      },
      {
        "source": "pubmed",
        "pmid": "41870735",
        "title": "Efficacy and safety of trastuzumab biosimilar CT-P6 plus SOX or CapeOX in HER2-positive advanced gastric cancer: a multicenter phase II KSCC-TROX study.",
        "authors": "Oki E et al.",
        "journal": "Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41870735/",
        "sentiment": {
          "label": "negative",
          "score": -0.153,
          "confidence": 0.15
        }
      },
      {
        "source": "pubmed",
        "pmid": "41866411",
        "title": "Efficacy and safety of peptide radionuclide therapy with (177)Lu-DOTATATE in Japanese patients with advanced neuroendocrine neoplasm: a multicenter retrospective study (JON2203-N).",
        "authors": "Okamoto K et al.",
        "journal": "Journal of gastroenterology",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41866411/",
        "sentiment": {
          "label": "positive",
          "score": 0.586,
          "confidence": 0.59
        }
      },
      {
        "source": "pubmed",
        "pmid": "41864749",
        "title": "Survival outcome of VATS compared with open lobectomy for lung cancer: an individual patient data meta-analysis of randomised trials.",
        "authors": "Harris RA et al.",
        "journal": "Lancet (London, England)",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41864749/",
        "sentiment": {
          "label": "negative",
          "score": -0.66,
          "confidence": 0.66
        }
      },
      {
        "source": "pubmed",
        "pmid": "41861751",
        "title": "Sacituzumab govitecan in patients with metastatic breast cancer: pooled safety analysis of data from patients in North America, Europe, and Asia.",
        "authors": "Rugo HS et al.",
        "journal": "ESMO open",
        "date": "2026 Mar 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41861751/",
        "sentiment": {
          "label": "negative",
          "score": -0.382,
          "confidence": 0.38
        }
      },
      {
        "source": "pubmed",
        "pmid": "41861516",
        "title": "Multidisciplinary international expert consensus recommendations on tissue acquisition in non-small cell lung cancer.",
        "authors": "Lee P et al.",
        "journal": "EBioMedicine",
        "date": "2026 Mar 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41861516/",
        "sentiment": {
          "label": "negative",
          "score": -0.46,
          "confidence": 0.46
        }
      },
      {
        "source": "pubmed",
        "pmid": "41858873",
        "title": "Tolerance and Resistance to Targeted Therapy in NSCLC: Emerging Concepts and Strategies.",
        "authors": "Sanchez-Cespedes M et al.",
        "journal": "JTO clinical and research reports",
        "date": "2026-04-02",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41858873/",
        "sentiment": {
          "label": "positive",
          "score": 0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "pubmed",
        "pmid": "41851476",
        "title": "Real-world analysis of androgen receptor inhibitors in US patients with nonmetastatic castration-resistant prostate cancer: DEAR-EXT study.",
        "authors": "Shore ND et al.",
        "journal": "Prostate cancer and prostatic diseases",
        "date": "2026 Mar 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41851476/",
        "sentiment": {
          "label": "negative",
          "score": -0.751,
          "confidence": 0.75
        }
      },
      {
        "source": "pubmed",
        "pmid": "41849281",
        "title": "Implementing a successful patient navigation program for follow-up colonoscopy: Lessons from the PRECISE study.",
        "authors": "Thompson JH et al.",
        "journal": "PloS one",
        "date": "2026-04-02",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41849281/",
        "sentiment": {
          "label": "positive",
          "score": 0.586,
          "confidence": 0.59
        }
      },
      {
        "source": "pubmed",
        "pmid": "41847154",
        "title": "Clinical Outcomes and Safety of Concurrent Chemoradiotherapy in EGFR-Mutant Unresectable Stage III NSCLC.",
        "authors": "Takamori S et al.",
        "journal": "JTO clinical and research reports",
        "date": "2026-04-02",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41847154/",
        "sentiment": {
          "label": "positive",
          "score": 0.421,
          "confidence": 0.42
        }
      },
      {
        "source": "pubmed",
        "pmid": "41843267",
        "title": "SEOM-TTCC clinical guidelines for the treatment of head and neck cancer (2025).",
        "authors": "Arrazubi V et al.",
        "journal": "Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico",
        "date": "2026 Mar 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41843267/",
        "sentiment": {
          "label": "negative",
          "score": -0.66,
          "confidence": 0.66
        }
      },
      {
        "source": "pubmed",
        "pmid": "41840238",
        "title": "First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial.",
        "authors": "Shitara K et al.",
        "journal": "Nature medicine",
        "date": "2026 Mar 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41840238/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41832914",
        "title": "Impact of peritoneal metastasis on overall survival in patients with advanced endometrial cancer receiving lenvatinib plus pembrolizumab.",
        "authors": "Boku S et al.",
        "journal": "Discover oncology",
        "date": "2026 Mar 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41832914/",
        "sentiment": {
          "label": "negative",
          "score": -0.527,
          "confidence": 0.53
        }
      },
      {
        "source": "pubmed",
        "pmid": "41830752",
        "title": "Real-world effectiveness of palbociclib in combination with an aromatase inhibitor in HR+/HER2- bone-only metastatic breast cancer.",
        "authors": "Brufsky A et al.",
        "journal": "Breast (Edinburgh, Scotland)",
        "date": "2026-04-02",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41830752/",
        "sentiment": {
          "label": "negative",
          "score": -0.691,
          "confidence": 0.69
        }
      },
      {
        "source": "pubmed",
        "pmid": "41830429",
        "title": "Telemedicine as a gateway to early-phase oncology trials: lessons from 14 000 patients and future directions for global access and equity.",
        "authors": "Torrado C et al.",
        "journal": "The oncologist",
        "date": "2026 Mar 9",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41830429/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41825704",
        "title": "Coupled-enzyme assay for MTAP activity in biological samples.",
        "authors": "Gilaj N et al.",
        "journal": "Analytical biochemistry",
        "date": "2026 Mar 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41825704/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41825178",
        "title": "Increased detection of NRG1 fusions in non-squamous non-small cell lung cancer using combined DNA and RNA sequencing in a real-world cohort.",
        "authors": "Araújo BJ et al.",
        "journal": "Lung cancer (Amsterdam, Netherlands)",
        "date": "2026 Mar 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41825178/",
        "sentiment": {
          "label": "negative",
          "score": -0.511,
          "confidence": 0.51
        }
      },
      {
        "source": "pubmed",
        "pmid": "41819545",
        "title": "Evaluation of mixed response in tumor size and survival in patients with rare cancers treated with dual checkpoint inhibitor therapy (DART SWOG S1609).",
        "authors": "Chae YK et al.",
        "journal": "Journal for immunotherapy of cancer",
        "date": "2026 Mar 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41819545/",
        "sentiment": {
          "label": "negative",
          "score": -0.44,
          "confidence": 0.44
        }
      },
      {
        "source": "pubmed",
        "pmid": "41819104",
        "title": "Cell-type-specific transposon demethylation and TAD remodeling in aging mouse brain.",
        "authors": "Zeng Q et al.",
        "journal": "Cell",
        "date": "2026 Mar 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41819104/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41817930",
        "title": "ASO Visual Abstract: Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer-Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study.",
        "authors": "Kuemmel S et al.",
        "journal": "Annals of surgical oncology",
        "date": "2026 Mar 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41817930/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41810446",
        "title": "Comparable remission and health care use in real-world inflammatory bowel disease patients initiating originator biologics vs biosimilars.",
        "authors": "Moura CS et al.",
        "journal": "World journal of gastroenterology",
        "date": "2026 Mar 7",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41810446/",
        "sentiment": {
          "label": "positive",
          "score": 0.494,
          "confidence": 0.49
        }
      },
      {
        "source": "pubmed",
        "pmid": "41809424",
        "title": "Bridging paradigms and shaping the future of resectable gastric cancer: a narrative review of the post-MATTERHORN era.",
        "authors": "Okemoto D et al.",
        "journal": "Gastroenterology report",
        "date": "2026-04-02",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41809424/",
        "sentiment": {
          "label": "negative",
          "score": -0.66,
          "confidence": 0.66
        }
      },
      {
        "source": "pubmed",
        "pmid": "41808570",
        "title": "Review of patient-reported outcomes in EMPOWER-Lung 1 in patients with advanced non-small cell lung cancer treated with cemiplimab versus chemotherapy.",
        "authors": "Gandara DR et al.",
        "journal": "Cancer",
        "date": "2026 Mar 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41808570/",
        "sentiment": {
          "label": "negative",
          "score": -0.527,
          "confidence": 0.53
        }
      },
      {
        "source": "pubmed",
        "pmid": "41808091",
        "title": "Recovery from fulminant immune-related myocarditis induced by ipilimumab plus nivolumab in malignant pleural mesothelioma: a case report.",
        "authors": "Konya Y et al.",
        "journal": "BMC pulmonary medicine",
        "date": "2026 Mar 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41808091/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41807638",
        "title": "Advances in the management of metastatic gastric cancer: current strategies and emerging therapeutics.",
        "authors": "Choo J et al.",
        "journal": "Nature reviews. Clinical oncology",
        "date": "2026 Mar 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41807638/",
        "sentiment": {
          "label": "negative",
          "score": -0.66,
          "confidence": 0.66
        }
      },
      {
        "source": "pubmed",
        "pmid": "41793510",
        "title": "A phase II study of atezolizumab in combination with stereotactic radiation for patients with triple-negative breast cancer and brain metastasis.",
        "authors": "Giordano A et al.",
        "journal": "Breast cancer research and treatment",
        "date": "2026 Mar 7",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41793510/",
        "sentiment": {
          "label": "negative",
          "score": -0.66,
          "confidence": 0.66
        }
      },
      {
        "source": "pubmed",
        "pmid": "41792532",
        "title": "Ensuring High-Quality Rectal Cancer Surgery in an Era of Increasing Treatment Complexity.",
        "authors": "Brown KGM et al.",
        "journal": "Annals of surgical oncology",
        "date": "2026 Mar 6",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41792532/",
        "sentiment": {
          "label": "negative",
          "score": -0.511,
          "confidence": 0.51
        }
      },
      {
        "source": "pubmed",
        "pmid": "41790338",
        "title": "Clinical development of molecular residual disease (MRD) and multi-cancer early detection (MCED) using liquid biopsy multiomics with artificial intelligence (AI).",
        "authors": "Shibuki T et al.",
        "journal": "International journal of clinical oncology",
        "date": "2026 Mar 6",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41790338/",
        "sentiment": {
          "label": "positive",
          "score": 0.477,
          "confidence": 0.48
        }
      },
      {
        "source": "pubmed",
        "pmid": "41781623",
        "title": "Homologous recombination deficiency and hemizygosity drive resistance in breast cancer.",
        "authors": "Safonov A et al.",
        "journal": "Nature",
        "date": "2026 Mar 4",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41781623/",
        "sentiment": {
          "label": "negative",
          "score": -0.66,
          "confidence": 0.66
        }
      },
      {
        "source": "pubmed",
        "pmid": "41779341",
        "title": "Comparison of first-line cetuximab and panitumumab plus doublet chemotherapies for left-sided colorectal cancer: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum.",
        "authors": "Kawagoe R et al.",
        "journal": "International journal of clinical oncology",
        "date": "2026 Mar 4",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41779341/",
        "sentiment": {
          "label": "negative",
          "score": -0.869,
          "confidence": 0.87
        }
      },
      {
        "source": "pubmed",
        "pmid": "41761577",
        "title": "Real-world outcomes of encorafenib, cetuximab ± binimetinib for BRAF‑mutated metastatic colorectal cancer: the BEETS (JACCRO CC‑18) study.",
        "authors": "Kotani D et al.",
        "journal": "The oncologist",
        "date": "2026 Mar 9",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41761577/",
        "sentiment": {
          "label": "negative",
          "score": -0.66,
          "confidence": 0.66
        }
      },
      {
        "source": "pubmed",
        "pmid": "41616774",
        "title": "Emerging landscape of KRAS inhibitors in cancer treatment.",
        "authors": "Riedl JM et al.",
        "journal": "Cancer cell",
        "date": "2026 Mar 9",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41616774/",
        "sentiment": {
          "label": "negative",
          "score": -0.751,
          "confidence": 0.75
        }
      },
      {
        "source": "reddit",
        "subreddit": "getagraph",
        "title": "Buy Signal Guardant Health Inc - 1 Apr 2026 @ 11:33 -> USD93.35",
        "text": "Ticker: **GH**\n\nExchange: **NASDAQ**\n\nTime: **1 Apr 2026 @ 11:33**\n\nPrice: **USD93.35**\n\nLink: https://getagraph.com/NASDAQ/stock/live-signals/GH/ENG",
        "author": "jvc72",
        "score": 1,
        "num_comments": 0,
        "date": "2026-04-01",
        "url": "https://reddit.com/r/getagraph/comments/1s9o0e9/buy_signal_guardant_health_inc_1_apr_2026_1133/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "reddit",
        "subreddit": "getagraph",
        "title": "Buy Signal Guardant Health Inc - 3 Mar 2026 @ 15:35 -> USD93.91",
        "text": "Ticker: **GH**\n\nExchange: **NASDAQ**\n\nTime: **3 Mar 2026 @ 15:35**\n\nPrice: **USD93.91**\n\nLink: https://getagraph.com/NASDAQ/stock/live-signals/GH/ENG",
        "author": "jvc72",
        "score": 1,
        "num_comments": 0,
        "date": "2026-03-03",
        "url": "https://reddit.com/r/getagraph/comments/1rk0rxn/buy_signal_guardant_health_inc_3_mar_2026_1535/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "reddit",
        "subreddit": "DeepFuckingValue",
        "title": "After-Hours Gainers and Losers for Today (March 24, 2026) 📈 📉",
        "text": "Here are today's top after-hours performers showing the biggest moves after regular trading hours.\n\n## 📈 After-Hours Gainers:\n\n| Symbol | Company | After-Hours | Regular Hours | Change | %Change |\n|:-------|:--------|:----------:|:-------------:|:------:|:-------:|\n| [ARM](https://marketrodeo.com/asset/ARM) | Arm Holdings plc American Depositary Shares | 144.76 | 134.96 | +9.80 | +7.26% |\n| [LTM](https://marketrodeo.com/asset/LTM) | LATAM Airlines Group S.A. | 51.50 | 49.03 | +2.47 | +5.04% |\n| ",
        "author": "MarketRodeo",
        "score": 3,
        "num_comments": 0,
        "date": "2026-03-24",
        "url": "https://reddit.com/r/DeepFuckingValue/comments/1s2qaha/afterhours_gainers_and_losers_for_today_march_24/",
        "sentiment": {
          "label": "negative",
          "score": -0.527,
          "confidence": 0.53
        }
      },
      {
        "source": "reddit",
        "subreddit": "DeepFuckingValue",
        "title": "After-Hours Gainers and Losers for Today (March 13, 2026) 📈 📉",
        "text": "Here are today's top after-hours performers showing the biggest moves after regular trading hours.\n\n## 📈 After-Hours Gainers:\n\n| Symbol | Company | After-Hours | Regular Hours | Change | %Change |\n|:-------|:--------|:----------:|:-------------:|:------:|:-------:|\n| [CHKP](https://marketrodeo.com/asset/CHKP) | Check Point Software Technologies Ltd. | 181.23 | 153.65 | +27.58 | +17.95% |\n| [STLD](https://marketrodeo.com/asset/STLD) | Steel Dynamics, Inc. | 199.24 | 170.60 | +28.64 | +16.79% |\n| ",
        "author": "MarketRodeo",
        "score": 3,
        "num_comments": 1,
        "date": "2026-03-13",
        "url": "https://reddit.com/r/DeepFuckingValue/comments/1rszlgw/afterhours_gainers_and_losers_for_today_march_13/",
        "sentiment": {
          "label": "negative",
          "score": -0.527,
          "confidence": 0.53
        }
      },
      {
        "source": "reddit",
        "subreddit": "Swing_Trader_Trading",
        "title": "Middle East war begins – stocks drop – Update 03/09/26",
        "text": "[Blog Post:](https://positiontrader.blog/2026/03/09/middle-east-war-begins-stocks-drop-update-03-09-26/)\n\nhttps://preview.redd.it/kf19dhculjng1.png?width=877&format=png&auto=webp&s=5f11966e2029af18cd9e91fec37a0655543a614d\n\n* [**Quant 30** ](https://positiontrader.blog/2026/03/09/middle-east-war-begins-stocks-drop-update-03-09-26/#portfolio)**– Up over 26% since June 2025**\n* **Quant Weekly – Up over 27% since June** **2025**\n* **Legacy – Up over 270% since April 2023**\n* [**Education** ](https:/",
        "author": "Swing_Trader_Trading",
        "score": 2,
        "num_comments": 1,
        "date": "2026-03-09",
        "url": "https://reddit.com/r/Swing_Trader_Trading/comments/1roycq7/middle_east_war_begins_stocks_drop_update_030926/",
        "sentiment": {
          "label": "negative",
          "score": -0.718,
          "confidence": 0.72
        }
      },
      {
        "source": "reddit",
        "subreddit": "Swing_Trader_Trading",
        "title": "Extreme fear grips the stock market – stock drop slows – Update 03/16/26",
        "text": "[Blog Post:](https://positiontrader.blog/2026/03/16/extreme-fear-grips-the-stock-market-stock-drop-slows-update-03-16-26/)\n\nhttps://preview.redd.it/ol6riok5g2pg1.png?width=1793&format=png&auto=webp&s=5d0155bc6fd0f1b0fafa9d68bccc95c29c00823d\n\n* [**Quant 30** ](https://positiontrader.blog/2026/03/16/extreme-fear-grips-the-stock-market-stock-drop-slows-update-03-16-26/#portfolio)**– Up over 24% since June 2025**\n* **Quant Weekly – Up over 26% since June** **2025**\n* **Legacy – Up over 270% since Ap",
        "author": "Swing_Trader_Trading",
        "score": 2,
        "num_comments": 0,
        "date": "2026-03-16",
        "url": "https://reddit.com/r/Swing_Trader_Trading/comments/1rv7j7d/extreme_fear_grips_the_stock_market_stock_drop/",
        "sentiment": {
          "label": "negative",
          "score": -0.68,
          "confidence": 0.68
        }
      },
      {
        "source": "reddit",
        "subreddit": "pancreaticcancer",
        "title": "Guardant liquid biopsy BRCA2",
        "text": "anyone have Guardant and have something as 0.3% and it be relevant on tissue. my husband has several markers but two of ones that popped up as low level BRCA2 Y3308 as 0.3% and wondering if it's just noise. waiting for tissue but just curious. He has some that are higher but I'm pretty sure they can't be targeted. Thanks in advance.",
        "author": "Any_Tumbleweed_7601",
        "score": 5,
        "num_comments": 9,
        "date": "2026-03-29",
        "url": "https://reddit.com/r/pancreaticcancer/comments/1s71r2e/guardant_liquid_biopsy_brca2/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "reddit",
        "subreddit": "Quantisnow",
        "title": "Guardant Health's InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan",
        "text": "",
        "author": "Quantisnow",
        "score": 1,
        "num_comments": 0,
        "date": "2026-03-30",
        "url": "https://reddit.com/r/Quantisnow/comments/1s7opko/guardant_healths_infinityai_realworld_evidence/",
        "sentiment": {
          "label": "positive",
          "score": 0.735,
          "confidence": 0.74
        }
      },
      {
        "source": "reddit",
        "subreddit": "Quantisnow",
        "title": "Verana Health and Guardant Health Partner to Advance Precision Medicine with Real-World Data",
        "text": "",
        "author": "Quantisnow",
        "score": 1,
        "num_comments": 0,
        "date": "2026-03-24",
        "url": "https://reddit.com/r/Quantisnow/comments/1s2dj2p/verana_health_and_guardant_health_partner_to/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "reddit",
        "subreddit": "RWATimes",
        "title": "Guardant Health to Present 28 Abstracts Highlighting Advances in Tumor Typing, Therapy Selection ...",
        "text": "![](https://mms.businesswire.com/media/20260318529389/en/1330243/22/GuardantHealthLogo_TM_RGB-2C.jpg)\n\n-Guardant Reveal demonstrates expanded utility in identifying new, primary cancers during minimal residual disease (MRD) monitoringStudies show strong performance of Guardant360 Tissue in determining  ...\n\n **Details:**\n- **Published:** 18/03/2026 12:05 (UTC)\n- **📊 Characteristics Score:**\n  > **Asset Type:** *others*\n  > **Sentiment:** `0.3`\n  > **Entropy:** `0.75`\n  > **Relevance:** `0.9`\n  >",
        "author": "rwatimes",
        "score": 1,
        "num_comments": 0,
        "date": "2026-03-22",
        "url": "https://reddit.com/r/RWATimes/comments/1s0dfot/guardant_health_to_present_28_abstracts/",
        "sentiment": {
          "label": "negative",
          "score": -0.382,
          "confidence": 0.38
        }
      },
      {
        "source": "reddit",
        "subreddit": "Quantisnow",
        "title": "Guardant Health to Present 28 Abstracts Highlighting Advances in Tumor Typing, Therapy Selection and Expanded Utility of Multiomic Tissue and Liquid Biopsy Testing at AACR 2026",
        "text": "",
        "author": "Quantisnow",
        "score": 1,
        "num_comments": 0,
        "date": "2026-03-18",
        "url": "https://reddit.com/r/Quantisnow/comments/1rx23dm/guardant_health_to_present_28_abstracts/",
        "sentiment": {
          "label": "negative",
          "score": -0.382,
          "confidence": 0.38
        }
      },
      {
        "source": "reddit",
        "subreddit": "Quantisnow",
        "title": "Guardant Health Launches Shield Multi-Cancer Detection (MCD) Test in Multiple Markets in Asia with Manulife Partnership",
        "text": "",
        "author": "Quantisnow",
        "score": 1,
        "num_comments": 0,
        "date": "2026-03-16",
        "url": "https://reddit.com/r/Quantisnow/comments/1rv7mrt/guardant_health_launches_shield_multicancer/",
        "sentiment": {
          "label": "positive",
          "score": 0.2,
          "confidence": 0.2
        }
      },
      {
        "source": "reddit",
        "subreddit": "Quantisnow",
        "title": "New Guardant Health/Harris Poll Survey Shows 92% of All Eligible Americans Believe Colorectal Cancer Blood Tests Should be Accessible and Covered Similar to Medicare",
        "text": "",
        "author": "Quantisnow",
        "score": 2,
        "num_comments": 0,
        "date": "2026-03-13",
        "url": "https://reddit.com/r/Quantisnow/comments/1rsljb0/new_guardant_healthharris_poll_survey_shows_92_of/",
        "sentiment": {
          "label": "negative",
          "score": -0.66,
          "confidence": 0.66
        }
      },
      {
        "source": "reddit",
        "subreddit": "Quantisnow",
        "title": "Guardant Health's Shield Blood-based Screening Test for Colorectal Cancer Now Accessible Through National Test Ordering and Collection Network of Quest Diagnostics",
        "text": "",
        "author": "Quantisnow",
        "score": 2,
        "num_comments": 0,
        "date": "2026-03-10",
        "url": "https://reddit.com/r/Quantisnow/comments/1rpv5qg/guardant_healths_shield_bloodbased_screening_test/",
        "sentiment": {
          "label": "negative",
          "score": -0.66,
          "confidence": 0.66
        }
      },
      {
        "source": "reddit",
        "subreddit": "Penny_Stock_USA",
        "title": "Guardant’s new Shield screening tour shows blood-based testing is moving into real-world rollout",
        "text": "https://preview.redd.it/c09uxs4b52ng1.png?width=315&format=png&auto=webp&s=265801915d05560931fe4bd597ec820cbe50a057\n\nToday Guardant Health launched \"Shield Across America\", a coast-to-coast mobile screening tour that will bring its Shield colorectal cancer blood test to over 100 U.S. communities, with a stated focus on rural areas that have low screening rates and higher CRC incidence and mortality.\n\nGuardant is tying the rollout to real-world completion behavior, citing 93% patient adherence in",
        "author": "UnlicensedWizard78",
        "score": 2,
        "num_comments": 0,
        "date": "2026-03-04",
        "url": "https://reddit.com/r/Penny_Stock_USA/comments/1rkqiwn/guardants_new_shield_screening_tour_shows/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "reddit",
        "subreddit": "Quantisnow",
        "title": "Guardant Health Launches Coast-to-Coast Screening Tour, Bringing Shield Colon Cancer Blood Test to Over 100 Communities Across America",
        "text": "",
        "author": "Quantisnow",
        "score": 1,
        "num_comments": 0,
        "date": "2026-03-04",
        "url": "https://reddit.com/r/Quantisnow/comments/1rkjntr/guardant_health_launches_coasttocoast_screening/",
        "sentiment": {
          "label": "negative",
          "score": -0.66,
          "confidence": 0.66
        }
      },
      {
        "source": "reddit",
        "subreddit": "Quantisnow",
        "title": "Actor and Cancer Advocate Patrick Dempsey Partners with Guardant Health to Raise Awareness about Colorectal Cancer Screening and Shield Blood Test, Sharing His Experience Getting Screened",
        "text": "",
        "author": "Quantisnow",
        "score": 1,
        "num_comments": 0,
        "date": "2026-03-03",
        "url": "https://reddit.com/r/Quantisnow/comments/1rjnjjd/actor_and_cancer_advocate_patrick_dempsey/",
        "sentiment": {
          "label": "negative",
          "score": -0.791,
          "confidence": 0.79
        }
      },
      {
        "source": "reddit",
        "subreddit": "exactsciences",
        "title": "Exact Sciences Is Now Abbott!",
        "text": "As result of the Merger, on March 23, 2026, a change in control of Exact occurred, and Exact is now a direct, wholly owned subsidiary of Abbott Laboratories \n\nIt has been one heckuva run for long-time Exact Sciences shareholders! \n\nA roller coaster ride for sure at times. But always, for me at least, more than just an investment, but about being a part of the Company's mission to eradicate cancer and alleviate human suffering.\n\nAnd so many memories! \n\nWho can forget the fiasco in 2015, when Colo",
        "author": "Superchief440",
        "score": 17,
        "num_comments": 15,
        "date": "2026-03-23",
        "url": "https://reddit.com/r/exactsciences/comments/1s1mbwy/exact_sciences_is_now_abbott/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "reddit",
        "subreddit": "heraldry",
        "title": "After a year, I'm ready for critiques!",
        "text": "Hello all!      I started work on my assumed coat of arms this time last year, as trying to find if my Scottish ancestors possessed a COA was futile.\n\nAfter much research, deep contemplation, and countless edits, I think I finally have it right, and wishing for public opinion. I am open for your critiques! Before applying to and paying the $395 fee to the American College of Heraldry, as well as registering with the New England Committee on Heraldry, may I have your professional opinion and revi",
        "author": "EccentricArchivist",
        "score": 0,
        "num_comments": 17,
        "date": "2026-03-15",
        "url": "https://reddit.com/r/heraldry/comments/1ru63q2/after_a_year_im_ready_for_critiques/",
        "sentiment": {
          "label": "positive",
          "score": 0.42,
          "confidence": 0.42
        }
      },
      {
        "source": "reddit",
        "subreddit": "heraldry",
        "title": "Remade personal arms after last post",
        "text": "I wanted to make a coat of arms for my house, where I have rescued a lot of cats and dogs, which led to my online handle ''The Cat Fortress'' \n\nI wanted to incorporate green as it is my favorite color and the overall color palette accidentally (but fortuitously) reflects the colors of my country, Brazil\n\nFor the crest I went with a white cat with blue eyes to represent one of the nicest, best cats I've rescued, A white flamepoint named Brie which is an elderly cat\n\nwould you help me blazon this ",
        "author": "thecatfortress",
        "score": 54,
        "num_comments": 8,
        "date": "2026-03-24",
        "url": "https://reddit.com/r/heraldry/comments/1s2g5oz/remade_personal_arms_after_last_post/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "reddit",
        "subreddit": "heraldry",
        "title": "Help blazoning mirrored sets of daggers in saltire",
        "text": "please forgive the quick sketch, i put it together just as an example... i have been wondering how to blazon two sets of daggers in saltire, one set being inverted, without being repetitive. \n\nthe rough draft i had come up with for this example is “**Argent a pale Sable, charged with a lion’s head erased guardant proper, between in chief two daggers in saltire inverted Argent and in base two daggers in saltire Argent**”. i am now trying to properly condense it.\n\nmy primary question: **is there a",
        "author": "cailleachsith",
        "score": 29,
        "num_comments": 9,
        "date": "2026-03-30",
        "url": "https://reddit.com/r/heraldry/comments/1s7riey/help_blazoning_mirrored_sets_of_daggers_in_saltire/",
        "sentiment": {
          "label": "positive",
          "score": 0.402,
          "confidence": 0.4
        }
      },
      {
        "source": "reddit",
        "subreddit": "heraldry",
        "title": "How to blazon properly/order of words",
        "text": "This is a prototype of my arms, I have some tweaks to make of shades of colors, but they'll stay the same. \n\n  \nI understand the components of it, but am confused on the order. I know its a field of argent, a beaver rampant proper, (how do you say holding) a key or, and then idk how to say on a azure Chevron, with a crest of a cat sejant argent)",
        "author": "Cadet-Cryyx",
        "score": 9,
        "num_comments": 7,
        "date": "2026-03-25",
        "url": "https://reddit.com/r/heraldry/comments/1s3cig9/how_to_blazon_properlyorder_of_words/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "reddit",
        "subreddit": "heraldry",
        "title": "Book Suggestions on Heraldry..",
        "text": "Hi everybody, im collecting books on heraldry as much as find anywhere but most of them old editions with b&w editions which doesnt bring any good to comprehend the essence at all.\n\nRecently came across with [this one](https://www.amazon.com/Illustrated-Book-Heraldry-International-Contemporary/dp/0754834603/) (see the second pic and continuous ones) *Lorenz Books Publishing by Stephen Slater*. And seems pretty comprehensive. What do you think about it? Do you have any other suggestions?\n\nThank y",
        "author": "lastmonday07",
        "score": 33,
        "num_comments": 5,
        "date": "2026-03-18",
        "url": "https://reddit.com/r/heraldry/comments/1rxe188/book_suggestions_on_heraldry/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "reddit",
        "subreddit": "heraldry",
        "title": "Coat of arms of a fictitious country, created in the style of Vexald [blazon, feedback]",
        "text": "Coat of arms of a fictitious country, created in the style of Vexald. \n\nDoes anyone have any feedback on or issues with its heraldic form (\"correctness\")? \n\nWould also be grateful if someone more knowledgeable than I am in this field would be so kind as to generate a blazon for the full achievement. The blade being held by the lion passant guardant in the crest and escutcheon is known as a keris, which is also present in the chief.",
        "author": "lanara-royal",
        "score": 30,
        "num_comments": 3,
        "date": "2026-03-28",
        "url": "https://reddit.com/r/heraldry/comments/1s5ussb/coat_of_arms_of_a_fictitious_country_created_in/",
        "sentiment": {
          "label": "positive",
          "score": 0.25,
          "confidence": 0.25
        }
      },
      {
        "source": "reddit",
        "subreddit": "lungcancer",
        "title": "Bio marker testing",
        "text": "Hi \n\nMy mom 56F Asian with multiple pulmonary nodules was diagnosed with non small cell lung cancer. She is a non smoker.  There is a high chance this is due to a mutation as per the pulmonologist. The oncologist that we are about to meet has sent the tissue and liquid biopsy to Caris. I have only heard of foundation one and guardant for lung cancer. Is Caris a good place to get biomarker testing done for lung cancer? Any insights or experiences with this company? ",
        "author": "Kind-Shake-953",
        "score": 11,
        "num_comments": 7,
        "date": "2026-03-14",
        "url": "https://reddit.com/r/lungcancer/comments/1rty5xk/bio_marker_testing/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      }
    ]
  }
}